09/ 076,575

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	AUG 22	Indexing from 1927 to 1936 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS 35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS 38	AUG 18	Simultaneous left and right truncation added to ANABSTR

09/ 076,575

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:34:21 ON 03 SEP 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:34:52 ON 03 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 SEP 2003  HIGHEST RN 577691-42-0
DICTIONARY FILE UPDATES:   1 SEP 2003  HIGHEST RN 577691-42-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10076575a.str

L1      STRUCTURE UPLOADED

=>
Uploading 10076575.str

L2      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 14:35:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 10803 TO ITERATE

100.0% PROCESSED 10803 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

```
=> s l2 ful
FULL SEARCH INITIATED 14:36:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2 TO ITERATE

100.0% PROCESSED       2 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L4            0 SEA SSS FUL L2

=> s 'dibenz[b,g]azocin
MISMATCHED QUOTE ''DIBENZ[B,G'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s 'dibenz[b,g]azocin'
         44984 'DIBENZ'
          2088 'B,G'
         11027 'AZOCIN'
L5          45 'DIBENZ[B,G]AZOCIN'
                ('DIBENZ'(W)'B,G'(W)'AZOCIN')

=> s 'dibenz'b,e][1,4]oxazepin'
MISMATCHED QUOTE '4]OXAZEPIN''
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s 'dibenz[b,e][1,4]oxazepin'
         44984 'DIBENZ'
         18496 'B,E'
        926873 '1,4'
          8726 'OXAZEPIN'
L6         203 'DIBENZ[B,E][1,4]OXAZEPIN'
                ('DIBENZ'(W)'B,E'(W)'1,4'(W)'OXAZEPIN')

=> s 'dibenz[d,g]dioxazocin'
         44984 'DIBENZ'
          2755 'D,G'
           111 'DIOXAZOCIN'
L7           0 'DIBENZ[D,G]DIOXAZOCIN'
                ('DIBENZ'(W)'D,G'(W)'DIOXAZOCIN')

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               341.70     341.91

FILE 'CAPLUS' ENTERED AT 14:41:00 ON 03 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 3 Sep 2003 VOL 139 ISS 10
FILE LAST UPDATED: 1 Sep 2003 (20030901/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:34:21 ON 03 SEP 2003)

FILE 'REGISTRY' ENTERED AT 14:34:52 ON 03 SEP 2003
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 0 S L1 FUL
L4 0 S L2 FUL
L5 45 S 'DIBENZ[B,G]AZOCIN'
L6 203 S 'DIBENZ[B,E][1,4]OXAZEPIN'
L7 0 S 'DIBENZ[D,G]DIOXAZOCIN'

FILE 'CAPLUS' ENTERED AT 14:41:00 ON 03 SEP 2003

=> s l5 or l6
18 L5
54 L6
L8 68 L5 OR L6

=> d l8 1- ibib abs fhitstr
YOU HAVE REQUESTED DATA FROM 68 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:927415 CAPLUS
DOCUMENT NUMBER: 138:14080
TITLE: Preparation of dihydrodiaryloxazepine derivatives for treatment of functional digestive tract diseases
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Tokumasu, Munetaka; Takahashi, Kazuyoshi; Hirasawa, Shigeo; Ezaki, Junko
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096891	A1	20021205	WO 2002-JP5193	20020529

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2001-161988 A 20010530
OTHER SOURCE(S): MARPAT 138:14080

GI



I

AB The title compds. I [ring G, J, K = benzene ring or N-contg. arom. ring; R1 - R8 = halo, H; R9 - R13 = H, halo, cyano, etc.; A = CH2, etc.; B = CO, etc.; or AB = CH:CH; D = CH2, etc.; or BD = CH2; XZ = CH2CH2, CH2CH2CH2, and Y = H; or YZ = CH2CH2CH2, CH2CH2CH2CH2, and X = H; further detail on X, Y, Z is given; a proviso is given] are prepd. Compds. of this invention are calcium channel antagonists with selectivity for the intestinal tract (IC50 values of 5.6 nM to 82.5 nM) and are useful in the treatment of functional digestive tract diseases. Formulations are given.

IT **477778-61-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)

RN 477778-61-3 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-[(1-fluorodibenz[b,e][1,4]oxazepin-5(11H)-yl)methyl]-1-pyrrolidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



⊙2 HCl

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:142672 CAPLUS
DOCUMENT NUMBER: 136:200094
TITLE: Preparation of biphenylcarboxamidoisoindoline derivatives as apolipoprotein B secretion inhibitors
INVENTOR(S): Yamada, Harutami; Ando, Akira; Kawanishi, Hiroyuki; Nagata, Koichi; Yasuhara, Mikiko
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014277	A1	20020221	WO 2001-JP6844	20010809
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001077728	A5	20020225	AU 2001-77728	20010809
JP 2003055345	A2	20030226	JP 2001-241482	20010809

PRIORITY APPLN. INFO.: JP 2000-243004 A 20000810
JP 2001-172918 A 20010607
WO 2001-JP6844 W 20010809
OTHER SOURCE(S): MARPAT 136:200094
GI



I

AB The title compds. I [ring A is a substituted or unsubstituted benzene ring; ring B is a substituted or unsubstituted benzene ring; Q is CO or CH2; and R is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted carbamoyl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like], useful as apolipoprotein B secretion inhibitors (no data), are prepd. Processes for the prepn. of I are claimed. For example, 2-(2-pyridyl)acetyl-5-[2-(4-trifluoromethylphenyl)benzoylamino]isoindoline was prepd.

IT **400726-74-1P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biphenylcarboxamidoisoindoline derivs. as apolipoprotein B secretion inhibitors)

RN 400726-74-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-2,3-dihydro-1H-isoindol-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:368136 CAPLUS
DOCUMENT NUMBER: 135:131732
TITLE: Synthesis of Novel .gamma.-Aminobutyric Acid (GABA) Uptake Inhibitors. 5.Preparation and Structure-Activity Studies of Tricyclic Analogues of Known GABA Uptake Inhibitors
AUTHOR(S): Andersen, Knud Erik; Sorensen, Jan L.; Lau, Jesper; Lundt, Behrend F.; Petersen, Hans; Huusfeldt, Per O.; Suzdak, Peter D.; Swedberg, Michael D. B.
CORPORATE SOURCE: Health Care Discovery, Novo Nordisk A/S, Malov, DK 2760, Den.
SOURCE: Journal of Medicinal Chemistry (2001), 44(13), 2152-2163

CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB On the basis of the SAR of a series of known .gamma.-aminobutyric acid (GABA) uptake inhibitors, including SKF 89976, new tricyclic analogs have been prepd. These novel compds. are derivs. of nipecotic acid, guvacine, and homo-.beta.-proline, substituted at the nitrogen of these amino acids by various lipophilic moieties such as (10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)alkoxyalkyl or (10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)alkoxyalkyl. The in vitro values for inhibition of [3H]-GABA uptake in rat synaptosomes was detd. for each compd. in this new series, and it was found that several of the novel compds. showed a high potency comparable with that of several ref. compds. Several of the novel compds. were also evaluated for their ability in vivo to inhibit clonic seizures induced by a 15 mg/kg (i.p.) dose of Me 6,7-dimethoxy-4-ethyl-.beta.-carboline-3-carboxylate (DMCM). One compd., (R)-1-(2-(2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid, was selected for further biol. investigations and showed a protective index comparable to or slightly better than that of the recently launched anticonvulsant tiagabine ((R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid).

IT **146844-18-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure-activity studies on tricyclic analogs of known GABA uptake inhibitors)

RN 146844-18-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[2-(6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)ethoxy]ethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:475653 CAPLUS
DOCUMENT NUMBER: 133:89556

09/ 076,575

TITLE: Preparation of oxazepine derivatives and drugs containing the same
INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040570	A1	20000713	WO 2000-JP71	20000111
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1142884	A1	20011010	EP 2000-900167	20000111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002099047	A1	20020725	US 2001-899928	20010709
US 6528504	B2	20030304		

PRIORITY APPLN. INFO.:
JP 1999-3268 A 19990108
JP 1999-3269 A 19990108
JP 1999-3270 A 19990108
WO 2000-JP71 W 20000111

OTHER SOURCE(S): MARPAT 133:89556
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; A = Q, Q1, Q2; R = H, Cl, (CH3)2N, CH3O; R1 = CH3O, N(CH3)2, H; R-R1 = OCH2O; n = 2, 3;], salts, stereoisomers, and drug compns. contg. I are prepd. and are useful in the treatment or prevention of motor function disorder of digestive tract, particularly intestinal diseases including irritable bowel syndrome. Thus, the title compds. (R)-5,11-Dihydro-5-[1-(4-methoxyphenethyl)-piperidin-2-ylmethyl]dibenzo[b,e][1,4] oxazepine and (R)-5,11-dihydro-5-[1-(4-dimethylaminophenethyl)-piperidin-2-ylmethyl]dibenzo[b, e][1,4]oxazepin were prepd. and tested.

IT **281677-38-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazepine derivs. and drugs contg. the same)

RN 281677-38-1 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-piperidinyl]ethyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:383927 CAPLUS
DOCUMENT NUMBER: 133:34425
TITLE: Pharmaceutical compositions containing N-substituted azaheterocyclic compounds for the treatment of indications related to angiogenesis
INVENTOR(S): Hansen, Anker Jon; Jorgensen, Tine Krogh; Olsen, Uffe Bang
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032193	A1	20000608	WO 1999-DK671	19991201
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1135129	A1	20010926	EP 1999-957964	19991201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003524611	T2	20030819	JP 2000-584888	19991201
US 2002045610	A1	20020418	US 2001-872127	20010601

PRIORITY APPLN. INFO.: DK 1998-1586 A 19981202
US 1998-111445P P 19981208
WO 1999-DK671 W 19991201
OTHER SOURCE(S): MARPAT 133:34425
AB The present invention relates to the use of N-substituted azaheterocyclic

compds. or salts thereof, for the treatment of conditions related to angiogenesis. N-substituted azaheterocyclic compds. decreased the vessel area of neovascularization of mouse cornea by 30-50%. A tablet contained a N-substituted azaheterocyclic compd. 100, silicone dioxide 1.5, microcryst. cellulose 70, modified cellulose gum 7.5, in the core, and hydroxypropyl Me cellulose 9, and Mywacett 9-40T 0.9 mg in the coating.

IT **170150-16-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. contg. N-substituted azaheterocyclic compds. for treatment of indications related to angiogenesis)

RN 170150-16-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-(3-dibenz[b,e][1,4]oxazepin-5(11H)-ylpropyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:277964 CAPLUS

DOCUMENT NUMBER: 132:308362

TITLE: Preparation of tricyclic compounds for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR)

INVENTOR(S): Jeppesen, Lone; Bury, Paul Stanley; Sauerberg, Per

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.; Reddy's Research Foundation

SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023425	A1	20000427	WO 1999-DK570	19991019

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9961902	A1	20000508	AU 1999-61902	19991019	
EP 1123279	A1	20010816	EP 1999-948738	19991019	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002527507	T2	20020827	JP 2000-577153	19991019	
US 6468996	B1	20021022	US 1999-419761	19991019	→ parent
US 2002103188	A1	20020801	US 2002-76574	20020208	
US 2002111344	A1	20020815	US 2002-76573	20020208	
US 2002115657	A1	20020822	US 2002-76575	20020208	
PRIORITY APPLN. INFO.:			DK 1998-1352	A 19981021	
			US 1998-105912P	P 19981028	
			US 1999-419761	A3 19991019	
			WO 1999-DK570	W 19991019	

OTHER SOURCE(S): MARPAT 132:308362
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1-R4 = H, halo, perhalomethyl, etc.; R1 and R2, R2 and R3, R3 and R4 may form (un)substituted cyclic ring contg. 5-7 carbon atoms; A = (un)substituted 5-6 membered cyclic ring; X = a bond, CH:CH, OCH2O, etc.; Ar = (un)substituted arylene, heteroarylene, divalent heterocyclic group; R5 = H, OH, halo, etc.; R6 = H, OH, halo, etc.; R7 = H, alkyl, alkenyl, etc.; R8 = H, alkyl, alkenyl, etc.; Y = O, S, NH, etc.; n = 1-4; m = 0-1], useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR) (e.g., in the treatment of diabetes and/or obesity), were prepd. and formulated. Thus, reacting 2-(10,11-dihydrodibenzo[b,f]azepin-5-yl)ethanol with Et 2-ethoxy-3-(4-hydroxyphenyl)propionate in the presence of triphenylphosphine and di-Et azodicarboxylate afforded 90% II. Compds. I are effective at 0.1-70 mg/day in the treatment of adult humans.

IT **265301-43-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic compds. for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR))

RN 265301-43-7 CAPLUS

CN Benzenepropanoic acid, 4-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethoxy)-.alpha.-ethoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:811383 CAPLUS
DOCUMENT NUMBER: 132:20799
TITLE: Media and system for comparative phenotype analysis of microorganism
INVENTOR(S): Bochner, Barry; Panomitros, Eugenia
PATENT ASSIGNEE(S): Biolog, Inc., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966066	A1	19991223	WO 1999-US13495	19990616
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6046021	A	20000404	US 1998-98066	19980616
EP 1088097	A1	20010404	EP 1999-928683	19990616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:
US 1998-98066 A 19980616
US 1995-421377 A2 19950412
US 1996-762656 A2 19961209
WO 1999-US13495 W 19990616

AB The present invention relates to growing and testing microorganisms in a multitest format. In particularly preferred embodiments, the multitest format utilizes a gel-forming matrix for the rapid screening of clin. and environmental cultures. The present invention is suited for the characterization of commonly encountered microorganisms (e.g., E. coli, S. aureus, etc.), as well as com. and industrially important organisms from various and diverse environments (e.g., the present invention is particularly suited for the growth and characterization of the actinomycetes and fungi). The present invention is also particularly suited for comparative anal. of phenotypic differences between cell types,

including strains of microorganisms that have been designated as the same genus and species, as well as other cell types (e.g., mammalian, insect, and plant cells).

IT **50354-32-0P**, Redox purple
RL: ARG (Analytical reagent use); ARU (Analytical role, unclassified); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(media and system for comparative phenotype anal. of microorganism)

RN 50354-32-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy-11-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:404950 CAPLUS
DOCUMENT NUMBER: 131:58843
TITLE: preparation of 3-piperidyl-4-oxoquinazoline derivatives as medicinal compositions
INVENTOR(S): Sato, Motohide; Katsushima, Takeo; Kinoshita, Hajime
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931085	A1	19990624	WO 1998-JP5628	19981211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 11228569	A2	19990824	JP 1998-288979	19981012
JP 2959765	B2	19991006		
ZA 9811315	A	19990630	ZA 1998-11315	19981210
AU 9915068	A1	19990705	AU 1999-15068	19981211
AU 717963	B2	20000406		
EP 970954	A1	20000112	EP 1998-959187	19981211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
BR 9807339	A	20000321	BR 1998-7339	19981211
NZ 337118	A	20000327	NZ 1998-337118	19981211
NO 9903868	A	19991012	NO 1999-3868	19990811
US 6235730	B1	20010522	US 1999-367242	19991026

09/ 076,575

PRIORITY APPLN. INFO.: JP 1997-362819 A 19971212
JP 1998-288979 A 19981012
WO 1998-JP5628 W 19981211

OTHER SOURCE(S): MARPAT 131:58843

GI



I

AB 3-Piperidyl-4-oxoquinazoline derivs. or pharmaceutically acceptable salts [I; R = amino substituted by optionally substituted aryl, heteroaryl, or cyclic amino such as dibenzazepine; n = integer from 1 to 4; R3, R4 = H, lower alkyl, etc.], having an excellent MTP-inhibitory activity, thus useful in inhibiting the formation of LDL causative of arteriosclerotic diseases and enabling the regulation of TG, cholesterol and lipoproteins such as LDL in the blood and cellular lipids via the regulation of the MTP activity, were prepd. I are expected also as a novel type of remedies or preventives for hyperlipemia or arteriosclerotic diseases and, moreover, as remedies or preventives for pancreatitis, obesity, hypercholesterolemia, hypertriglyceridemia, etc. Refluxing a mixt. of BrCH2CH2NPh2 and 3-(piperidin-4-yl)-3H-quinazolin-4-one contg. K2CO3 in MeCN gave 55% I (R = Ph2N, R3 = R4 = H, n = 2) (II). II.2HCl showed IC50 of 0.1 .mu.M against apolipoprotein B secretion and 0.6 .mu.M against triglyceride transport in vitro.

IT **227806-80-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-piperidyl-4-oxoquinazoline derivs. as medicinal compns.)

RN 227806-80-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[1-(2-dibenz[b,e][1,4]oxazepin-5(11H)-ylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:246872 CAPLUS
DOCUMENT NUMBER: 130:281580
TITLE: Preparation of thermally stable aminosulfur trifluorides as deoxofluorination agents
INVENTOR(S): Lal, Gauri Sankar; Pez, Guido Peter; Pesaresi, Reno Joseph, Jr.; Syvret, Robert George
PATENT ASSIGNEE(S): Air Products and Chemicals, Inc., USA
SOURCE: Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 908448	A1	19990414	EP 1998-118306	19980925
EP 908448	B1	20011114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6207860	B1	20010327	US 1997-939635	19970929
CA 2248407	AA	19990329	CA 1998-2248407	19980922
JP 11158141	A2	19990615	JP 1998-275235	19980929
JP 3357609	B2	20021216		
US 6242645	B1	20010605	US 2000-535682	20000323

PRIORITY APPLN. INFO.: US 1997-939635 A 19970929
OTHER SOURCE(S): MARPAT 130:281580
GI



I

AB Aminosulfur trifluorides I [m = 1-5; when m = 1 R1, R2 = aryl radicals, heterocyclyl, alkoxyalkyl and when m = 2-5 R1 = Ph and R2 = aryl], deoxofluorinating agents, were prepd. E.g., reaction of Ph2NH with SF4 gave Ph2NSF3 quant. Deoxofluorination of 4-tert-butylcyclohexanone by Ph2NSF3 gave 1,1-difluoro-4-tert-butylcyclohexane and 1-fluoro-4-tert-butyl-1-cyclohexene (96:4). The thermal stability of I was studied.

IT **222844-41-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of thermally stable aminosulfur trifluorides as deoxofluorination agents)

RN 222844-41-9 CAPLUS

CN Sulfur, (6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)trifluoro-, (T-4)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:194140 CAPLUS

DOCUMENT NUMBER: 130:223305

TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives as calcium antagonists

INVENTOR(S): Sakata, Katsutoshi; Tsuji, Takashi; Sasaki, Noriko; Takahashi, Kazuyoshi

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912925	A1	19990318	WO 1998-JP4071	19980910

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2304262	AA	19990318	CA 1998-2304262	19980910	
AU 9890014	A1	19990329	AU 1998-90014	19980910	
AU 740878	B2	20011115			
EP 1020466	A1	20000719	EP 1998-941803	19980910	
EP 1020466	B1	20030219			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
AT 232861	E	20030315	AT 1998-941803	19980910	
US 6562808	B1	20030513	US 2000-522946	20000310	

PRIORITY APPLN. INFO.: JP 1997-245669 A 19970910
JP 1997-245670 A 19970910
WO 1998-JP4071 W 19980910

OTHER SOURCE(S): MARPAT 130:223305

GI



I

AB The title compds. I [R1 - R5 = H, alkoxy, etc.; R6, R7 = H, hydroxy; Y1 = methylene, etc.] are prepd. I are useful in the treatment or prevention of intestinal diseases such as gastrointestinal tract dyskinesia, in particular, irritable bowel syndrome. In an in vitro test for calcium antagonism using ileum, (R)-5,11-Dihydro-5-[1-[2-(4-dimethylaminophenyl)ethyl]-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine dihydrochloride (II) in vitro showed IC50 of 35 nM; in an in vitro test for calcium antagonism using artery, II showed IC50 of 255 nM. I also showed high water soly.

IT **221159-49-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dihydrodibenzoxazepine derivs. as calcium antagonists)

RN 221159-49-5 CAPLUS

CN Benzenamine, 4-[2-[(2R)-2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:191357 CAPLUS
DOCUMENT NUMBER: 130:220169
TITLE: Gel matrix with redox purple for testing and characterizing microorganisms
INVENTOR(S): Bochner, Barry R.; Naleway, John J.
PATENT ASSIGNEE(S): Biolog, Inc., USA
SOURCE: U.S., 21 pp., Cont.-in-part of U.S. 5,627,045.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5882882	A	19990316	US 1996-762656	19961209
US 5627045	A	19970506	US 1995-421377	19950412
WO 9826270	A2	19980618	WO 1997-US22601	19971209
WO 9826270	A3	19980903		
W: JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6046021	A	20000404	US 1998-98066	19980616
US 5989853	A	19991123	US 1998-116078	19980715
US 6387651	B1	20020514	US 2000-574087	20000518
US 6472201	B1	20021029	US 2000-752168	20001229
US 2002110848	A1	20020815	US 2002-47048	20020114
US 2003148413	A1	20030807	US 2002-226436	20020823

PRIORITY APPLN. INFO.:
US 1995-421377 A2 19950412
US 1996-762656 A 19961209
US 1998-98066 A2 19980616
US 1999-333802 B1 19990615
US 2000-574087 A1 20000518
US 2000-752168 A3 20001229

AB The present invention is directed to methods and compns. for the characterization of various microorganisms. In particular, the present invention is suited for the characterization of commonly encountered microorganisms (e.g., E. coli, S. aureus, etc.), as well as com. and

industrially important organisms from various and diverse environments. For example, the present invention is particularly suited for the growth and characterization of the actinomycetes and fungi. The methods employ a testing system wherein an aq. suspension of microorganisms is introduced to one or more test substrates comprising redox purple (8-hydroxy-11-methyldibenz-[b,e][1,4]oxazepin-2-(11H)-one) and a gelling agent. The methods detect the response of the microorganisms to the test substrates. A testing device comprising a plurality of testing wells is well suited for the present invention. E. coli was tested on various carbon sources using redox purple sodium salt (prepn. given), resazurin sodium salt, or tetrazolium violet as the indicator. The gel matrix was carrageenan.

IT **50354-32-0P**, Redox purple
RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(gel matrix with redox purple for testing and characterizing microorganisms)

RN 50354-32-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy-11-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:406127 CAPLUS
DOCUMENT NUMBER: 129:78824
TITLE: Gel matrix with redox purple for growing and testing microorganisms
INVENTOR(S): Bochner, Barry R.; Naleway, John J.
PATENT ASSIGNEE(S): Biolog, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826270	A2	19980618	WO 1997-US22601	19971209
WO 9826270	A3	19980903		
W: JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5882882	A	19990316	US 1996-762656	19961209

PRIORITY APPLN. INFO.: US 1996-762656 A 19961209
US 1995-421377 A2 19950412

AB Methods and kits for the characterization of various microorganisms in a multitest format use a gel-forming matrix with redox purple and test substrates. In particular, the present invention is suited for the characterization of commonly encountered microorganisms (e.g., E. coli, S.

aureus, etc.), as well as com. and industrially important organisms from various and diverse environments. For example, the present invention is particularly suited for the growth and characterization of the actinomycetes and fungi. Growth of Aspergillus niger, Penicillium chrysogenum, and Trichoderma harzianum fungi on various carbon sources was tested using redox purple (prepn. given) in Gelrite in wells of a Biolog SF-N Microplate. For each carbon source utilized by the organism, the content of the well was colorless. The wells of unused carbon sources were blue.

IT **209187-17-7**
RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(gel matrix with redox purple for growing and testing microorganisms)

RN 209187-17-7 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy-11-methyl-, sodium salt (9CI) (CA INDEX NAME)



L8 ANSWER 13 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:623166 CAPLUS
DOCUMENT NUMBER: 127:293256
TITLE: Preparation and formulation of 5,11-dihydrodibenz[b,e][1,4]oxazepine derivatives for improving the motor function of the digestive tract
INVENTOR(S): Tanaka, Yuji; Misumi, Keiji; Kawakami, Yoshinari; Moriguchi, Masahiko; Takahashi, Kazuyoshi; Okamoto, Hiroki; Kamisaki, Toshiaki; Inoue, Kimihiro; Sato, Makoto
PATENT ASSIGNEE(S): Ajinomoto, Inc., Japan; Tanaka, Yuji; Misumi, Keiji; Kawakami, Yoshinari; Moriguchi, Masahiko; Takahashi, Kazuyoshi; Okamoto, Hiroki; Kamisaki, Toshiaki; Inoue, Kimihiro; Sato, Makoto
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9733885	A1	19970918	WO 1997-JP754	19970311

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,

GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

ZA 9702038	A	19970917	ZA 1997-2038	19970310	
TW 479057	B	20020311	TW 1997-86102931	19970310	
AU 9722335	A1	19971001	AU 1997-22335	19970311	
AU 704521	B2	19990422			
EP 889043	A1	19990107	EP 1997-905478	19970311	
EP 889043	B1	20010829			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
CN 1213371	A	19990407	CN 1997-193005	19970311	
CN 1085209	B	20020522			
BR 9707962	A	19990727	BR 1997-7962	19970311	
JP 3127469	B2	20010122	JP 1997-532434	19970311	
AT 204871	E	20010915	AT 1997-905478	19970311	
ES 2159843	T3	20011016	ES 1997-905478	19970311	
NO 9804162	A	19981105	NO 1998-4162	19980910	
US 6127361	A	20001003	US 1998-147012	19980911	
US 6436922	B1	20020820	US 2000-597409	20000619	

PRIORITY APPLN. INFO.: JP 1996-83104 A 19960311
WO 1997-JP754 W 19970311
US 1998-147012 A1 19980911

OTHER SOURCE(S): MARPAT 127:293256

GI



I

AB The title compds. I [R1, R2 = H, halo, etc.; or R1R2 = O(CH2)nO; n = 1 - 3; R3 = H, OH; R4, R5 = H, OH; or R4R5 = O] are prepd. I are calcium antagonists improving the motor function of the digestive tract. In an in vitro test for calcium antagonism using guinea pig ileum fragment, (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenz[b,e][1,4]oxazepine hydrochloride (II) showed IC50 of 85 nM; in the test for calcium antagonism using rat artery fragment, II showed IC50 of 200 nM. II showed no anticholinergic activity. II gave better improvement of the motor function of the digestive tract than nicardipine. In the test for hypotensive activity, II showed ED50 of > 1000 mg/kg p.o., vs. ED50 of 4 mg/kg p.o. for nicardipine.

IT **195991-57-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dihydrodibenzoxazepine derivs. for improving the motor function of the digestive tract)

RN 195991-57-2 CAPLUS

CN Benzonitrile, 4-[2-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)-1-pyrrolidinyl]ethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L8 ANSWER 14 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:501445 CAPLUS
DOCUMENT NUMBER: 127:121640
TITLE: Piperidinecarboxylic acid derivatives for treatment of non-insulin-dependent diabetes mellitus
INVENTOR(S): Olsen, Uffe Bang
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Olsen, Uffe Bang
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9722342	A1	19970626	WO 1996-DK520	19961210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9711383	A1	19970714	AU 1997-11383	19961210

PRIORITY APPLN. INFO.: DK 1995-1425 19951215
WO 1996-DK520 19961210
OTHER SOURCE(S): MARPAT 127:121640
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1, R2 = H, halogen, CF3, alkyl, alkoxy; R3 = OH, alkoxy; R4, R5 = H; R4R5 = bond; X = (CH2)s; X1 = (CH2)r; Y = NCH2, CHCH2, C:CH, CHCH:N, C:N; Z = O, S, CH2, CH2CH2, CH:CHCH2, CH2CH:CH, (CH2)3, CH:CH, OCH2; m = 1, n = 1; m = 2, n = 0; p, q = 0, 1; r = 2-4; s = 0-2] were

prepd. for use in the treatment of insulin resistance related to NIDDM (non-insulin-dependent diabetes mellitus) or aging (no data). Thus, 10,11-dihydro-5H-dibenz[b,f]azepine was treated with (ClCH2CH2)2O and Et (R)-3-piperidinecarboxylate, followed by ester hydrolysis to give the acid II.

IT **146844-43-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperidinecarboxylic acid derivs. for treatment of non-insulin-dependent diabetes mellitus)

RN 146844-43-1 CAPLUS

CN Ethanol, 2-[2-(11,12-dihydrodibenz[b,g]azocin-5(10H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 15 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:501427 CAPLUS
DOCUMENT NUMBER: 127:121639
TITLE: Piperidinecarboxylic acid derivatives for reducing blood glucose levels
INVENTOR(S): Olsen, Uffe Bang
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9722338	A1	19970626	WO 1996-DK524	19961212
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2239487	AA	19970626	CA 1996-2239487	19961212
AU 9711384	A1	19970714	AU 1997-11384	19961212
AU 704825	B2	19990506		
EP 869777	A1	19981014	EP 1996-942264	19961212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1204258	A	19990106	CN 1996-199019	19961212
BR 9612005	A	19990209	BR 1996-12005	19961212
JP 3048067	B2	20000605	JP 1997-522429	19961212
US 5741791	A	19980421	US 1996-766839	19961213
NO 9802732	A	19980814	NO 1998-2732	19980612

PRIORITY APPLN. INFO.: DK 1995-1426 A 19951215
WO 1996-DK524 W 19961212

OTHER SOURCE(S): MARPAT 127:121639

GI



I



II

AB Title compds. I [R1, R2 = H, halogen, CF3, alkyl, alkoxy; R3 = OH, alkoxy; R4, R5 = H, R4R5 = bond; X = O, S, (un)substituted CH2, CH2CH2, CH:CHCH2, CH2CH:CH, (CH2)3, CH:CH, (un)substituted NHCO, OCH2, CO, CS; Y = NCH2, CHCH2, C:CH; m = n = 1; m = 2, n = 0; p = 1-3] were prepd. for use in reducing blood glucose and/or inhibiting the secretion, circulation or effect of insulin antagonizing peptides like CGRP or amylin. Thus, acid II was prepd. from 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-one in 4 steps. II at 100 mg/L in drinking water lowered CGRP levels in mice from 260 to 152 pg/mL.

IT **170150-38-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperidinecarboxylic acid derivs. for reducing blood glucose levels)

RN 170150-38-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-(3-dibenz[b,e][1,4]oxazepin-5(11H)-ylpropyl)-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 16 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:324924 CAPLUS
DOCUMENT NUMBER: 127:65747
TITLE: Convenient synthesis of 6-substituted-2-chloro-5,12-dihydro-5-oxobenzoxazolo[3,2-a]quinolines and N-acylated-3-chlorodibenz[b,e][1,4]oxazepin-11(5H)-ones
AUTHOR(S): Chung, Sang J.; Joo, Keum Chan; Kim, Dong H.
CORPORATE SOURCE: Department of Chemistry and Center for Biofunctional Molecules, Pohang University of Science and Technology, Hyojadong Pohang, 790-784, S. Korea
SOURCE: Journal of Heterocyclic Chemistry (1997), 34(2), 485-488
CODEN: JHTCAD; ISSN: 0022-152X
PUBLISHER: HeteroCorporation
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:65747

AB Convenient synthesis of variously substituted 2-chloro-5,12-dihydro-5-oxobenzoxazolo[3,2-a]quinolines at the 6-position and N-acylated-3-chlorodibenz[b,e][1,4]oxazepin-11(5H)-ones are reported. The former compds. were obtained in 65-93% yield by simply heating N-acyl-4-chloro-N-(2-hydroxyphenyl)anthranilic acids in acetic anhydride for 4 h, and the latter by heating the sodium salt of N-acyl-4-chloro-N-(2-hydroxyphenyl)anthranilic acids with acetic anhydride.

IT **191337-64-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 191337-64-1 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-11(5H)-one, 3-chloro-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 17 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:913379 CAPLUS
DOCUMENT NUMBER: 123:313776
TITLE: Novel azaheterocyclic acids useful as analgesics and antiinflammatories.
INVENTOR(S): Andersen, Knud Erik; Olsen, Uffe Bang; Petersen, Hans; Groenvald, Frederik Christian; Sonnewald, Ursula; Joergensen, Tine Krogh; Andersen, Henrik Sune
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518793	A1	19950713	WO 1995-DK2	19950103
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IL 112222	A1	19991231	IL 1995-112222	19950102
CA 2180238	AA	19950713	CA 1995-2180238	19950103
AU 9513110	A1	19950801	AU 1995-13110	19950103
AU 691858	B2	19980528		
EP 738262	A1	19961023	EP 1995-904409	19950103
EP 738262	B1	20000419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1142226	A	19970205	CN 1995-191845	19950103
CN 1083431	B	20020424		
HU 75878	A2	19970528	HU 1996-1842	19950103
JP 09507239	T2	19970722	JP 1995-518275	19950103
JP 2944221	B2	19990830		
BR 9506452	A	19970902	BR 1995-6452	19950103
CZ 286109	B6	20000112	CZ 1996-1921	19950103
AT 191909	E	20000515	AT 1995-904409	19950103
ES 2147837	T3	20001001	ES 1995-904409	19950103
PL 180209	B1	20010131	PL 1995-315294	19950103
RU 2167152	C2	20010520	RU 1996-116134	19950103
NZ 277763	A	20011130	NZ 1995-277763	19950103
ZA 9500031	A	19960704	ZA 1995-31	19950104
NO 9602811	A	19960904	NO 1996-2811	19960703
FI 9602749	A	19960904	FI 1996-2749	19960704

PRIORITY APPLN. INFO.: DK 1994-19 A 19940104
DK 1994-1290 A 19941109
WO 1995-DK2 W 19950103
OTHER SOURCE(S): CASREACT 123:313776; MARPAT 123:313776
GI



I



II

AB The invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters I [R1, R2 = H, halo, CF3, alkyl, alkoxy; Y = NCH2, CHCH2, or C:CH, where only the 1st atom is within the ring; X = O, S, CR7R8, CH2CH2, CH:CHCH2, CH2CH:CH, CH2CH2CH2, CH:CH, NR9CO, OCH2, CO, SO; R7, R8, R9 = H, alkyl; p = 1, 2, 3; m = 1, 2; n = 1 when m = 1; or n = 0 when m = 2; R4 = R5 = H, or R4R5 = bond when m = 2; R6 = OH, alkoxy]. Also disclosed are prepn. of I, compns. contg. I, and use of I for treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiol. role by eliciting neurogenic pain or inflammation. For example, 10,11-dihydro-5H-dibenz[b,f]azepine was alkylated in the 5-position by NaH and 3-bromopropyl tetrahydro-2-pyranyl ether, followed by deprotection with HCl in refluxing aq. MeOH, to give the 5-(3-hydroxypropyl) deriv. This underwent mesylation with MeSO2Cl and Et3N, and the mesylate was treated with (R)-3-piperidinecarboxylic acid Et ester (tartrate salt) and then hydrolyzed to give title compd. II, isolated as the HCl salt (III). In the formalin-induced pain response test in mice, III at 0.1 mg/kg gave 50% inhibition.

IT **170150-38-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of azaheterocyclic acids as analgesics and antiinflammatories)

RN 170150-38-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-(3-dibenz[b,e][1,4]oxazepin-5(11H)-ylpropyl)-, ethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 18 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:808091 CAPLUS
DOCUMENT NUMBER: 123:188590
TITLE: A method of treating neurogenic inflammation
INVENTOR(S): Andersen, Knud Erik; Olsen, Uffe Bang
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518615	A1	19950713	WO 1995-DK3	19950103
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2180239	AA	19950713	CA 1995-2180239	19950103
AU 9513111	A1	19950801	AU 1995-13111	19950103
EP 735872	A1	19961009	EP 1995-904410	19950103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1142183	A	19970205	CN 1995-191801	19950103
HU 76281	A2	19970728	HU 1996-1826	19950103
JP 09507849	T2	19970812	JP 1995-518276	19950103
BR 9506453	A	19970902	BR 1995-6453	19950103
ZA 9500030	A	19960704	ZA 1995-30	19950104
NO 9602812	A	19960904	NO 1996-2812	19960703
FI 9602750	A	19960904	FI 1996-2750	19960704

PRIORITY APPLN. INFO.: DK 1994-20 19940104
WO 1995-DK3 19950103
OTHER SOURCE(S): MARPAT 123:188590
GI



I

AB A method of treating neurogenic inflammation comprises administering an effective amt. of a compd. I [R1,R2 = H, halogen, trifluoromethyl, C1-6 alkyl or alkoxy; Y = NCH2, CHCH2; C:CH, CHCH:N, C:N; X = O; Z = O, S, CH2, (CH2)2, CH:CHCH2, CH2CH:CH, (CH2)3, CH:CH, OCH2; R4, R5 = H or a bond; R6 = OH, C1-8 alkoxy; p, q = 0, 1; a = 0-2; b = 2-4; m = 1, 2; n = 0, 1] or a pharmaceutically acceptable salt thereof.

IT **146844-43-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(piperidine carboxylate derivs. as neurogenic inflammation inhibitors)

RN 146844-43-1 CAPLUS

CN Ethanol, 2-[2-(11,12-dihydrodibenz[b,g]azocin-5(10H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



L8 ANSWER 19 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1995:570871 CAPLUS

DOCUMENT NUMBER: 122:314588

TITLE: Preparation of sulfonamide and sulfonic ester derivatives each having tricyclic heterocyclic ring as antitumor agents

INVENTOR(S): Yoshino, Hiroshi; Ueda, Norihiro; Niijima, Jun; Haneda, Toru; Kotake, Yoshihiko; Yoshimatsu, Kentaro; Watanabe, Tatsuo; Nagasu, Takeshi; Tsukahara, Naoko; et al.

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9503279	A1	19950202	WO 1994-JP1231	19940726
W: CA, FI, NO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2144854	AA	19950202	CA 1994-2144854	19940726

EP 679641	A1	19951102	EP 1994-921819	19940726
EP 679641	B1	20021002		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
JP 08081441	A2	19960326	JP 1994-174643	19940726
AT 225334	E	20021015	AT 1994-921819	19940726
NO 9501108	A	19950523	NO 1995-1108	19950323
US 5834462	A	19981110	US 1995-397254	19950323
FI 9501416	A	19950517	FI 1995-1416	19950324
US 5854274	A	19981229	US 1996-760738	19961205
US 5846969	A	19981208	US 1997-873033	19970611

PRIORITY APPLN. INFO.:
JP 1993-202466 A 19930726
JP 1994-158870 A 19940711
WO 1994-JP1231 W 19940726
US 1995-397254 A3 19950323
US 1996-760738 A3 19961205

OTHER SOURCE(S): MARPAT 122:314588

GI For diagram(s), see printed CA Issue.

AB N-heterocyclylarylsulfonamide and heterocyclyl arylsulfonate derivs. each having a tricyclic hetero ring, represented by general formula G-SO2-L-M [G = a 5- or 6-membered arom. ring; L = O or NR1, wherein R1 = H or lower alkyl; M = a tricyclic structure selected from the members Q - Q5, wherein rings A and B represent each a 5 or 6-membered unsatd. ring; X = NR2 (wherein R2 = H or lower alkyl) or NHCO; Y = O, S(O)n, CR3R4, CO, NR5, CHR6CHR7, CR8:R9, NR10CO, N:CR11, OCHR12, S(O)nCH13, or NR14CHR15; Z = N or CR16, wherein n represents 0, 1 or 2; R3 - R13, R15, R16 = H or lower alkyl; R14 = H, lower alkyl, or lower acyl] are prepd. Thus, 107 mg 1-amino-10H-phenothiazine was dissolved in pyridine and a soln. of 115 mg 4-methoxybenzenesulfonyl chloride in THF was added followed by stirring the mixt. overnight at room temp. to give, after silica gel chromatog., a title compd. (I) (115 mg). I and phenothiazin-3-one deriv. (II) showed IC50 of 0.11 and 0.016 .mu.g/mL against KB cells (human nasal cavity cancer). A total of 49 I were prepd.

IT **163307-93-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-heterocyclylarylsulfonamide as antitumor agent)

RN 163307-93-5 CAPLUS

CN Benzenesulfonamide, N-(5,11-dihydrodibenz[b,e][1,4]oxazepin-6-yl)-4-methoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 20 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:543611 CAPLUS
DOCUMENT NUMBER: 122:286072

09/ 076,575

TITLE: Mediators suitable for the electrochemical regeneration of NADH, NADPH or their analogs
INVENTOR(S): Corey, Paul F.; Musho, Matthew K.
PATENT ASSIGNEE(S): Miles Inc., USA
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5393615	A	19950228	US 1994-190855	19940203
AU 9480280	A1	19950810	AU 1994-80280	19941207
AU 674463	B2	19961219		
EP 667397	A1	19950816	EP 1995-100849	19950123
EP 667397	B1	20011004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 206466	E	20011015	AT 1995-100849	19950123
ES 2161787	T3	20011216	ES 1995-100849	19950123
CA 2141494	AA	19950804	CA 1995-2141494	19950131
CA 2141494	C	20030114		
JP 07310194	A2	19951128	JP 1995-15025	19950201

PRIORITY APPLN. INFO.: US 1994-190855 A 19940203

AB Disclosed is the use of 9H-acridin-2-one and 11H-dibenz-[b,e][1,4]oxazepin-2-one compds. as mediators suitable for the electrochem. regeneration of the coenzymes dihydronicotinamide adenine dinucleotide (NADH), dihydronicotinamide adenine dinucleotide phosphate (NADPH), or their analogs.

IT **162964-68-3DP**, Dibenz[b,e][1,4]oxazepin-2(11H)-one, compds.
RL: ARU (Analytical role, unclassified); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(mediators for electrochem. regeneration of NADH or NADPH or their analogs)
RN 162964-68-3 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-2(11H)-one (9CI) (CA INDEX NAME)



L8 ANSWER 21 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:655579 CAPLUS
DOCUMENT NUMBER: 121:255579
TITLE: Photochemical synthesis of carbazoles from dibenzo[b,e][1,4]oxazepin-11(5H)-ones
AUTHOR(S): Kudav, Dinesh P.; Kulkarni, Narendra N.; Hosangadi, Bhaskar D.
CORPORATE SOURCE: Dep. Chem., Univ. Bombay, Bombay, 400 098, India
SOURCE: Journal of Chemical Research, Synopses (1994), (7), 266-7
CODEN: JRPSDC; ISSN: 0308-2342
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:255579
GI



I



II

AB Dibenzo[b,e][1,4]oxazepin-11(5H)-ones I (R1-R4 = H, Me, OMe, nitro) were prepd. from substituted anthranilic acid derivs. The photochem. cyclocondensation reaction of I furnished the carbazoles II (Same R1-R4).

IT **15676-55-8P**, Depsazidone
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for carbazole)

RN 15676-55-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepin-11(5H)-one (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 22 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1994:595901 CAPLUS

DOCUMENT NUMBER: 121:195901

TITLE: Immunogen and tracer reagents and methods for the immunochemical quantification of total doxepins in biological fluids

INVENTOR(S): Adamczyk, Maciej; Fishpaugh, Jeffrey R.; Johnson, Donald; Hruska, Robert E.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 738,400, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5332661	A	19940726	US 1992-916066	19920724
CA 2111467	AA	19930218	CA 1992-2111467	19920729
CA 2111467	C	20021112		
WO 9303372	A1	19930218	WO 1992-US6318	19920729
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9224206	A1	19930302	AU 1992-24206	19920729
EP 641440	A1	19950308	EP 1992-917171	19920729
EP 641440	B1	20001108		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 3071824	B2	20000731	JP 1993-503720	19920729

09/ 076,575

JP 06509797	T2	19941102			
AT 197508	E	20001111	AT 1992-917171		19920729
ES 2153361	T3	20010301	ES 1992-917171		19920729
US 5464767	A	19951107	US 1994-226809		19940412
PRIORITY APPLN. INFO.:			US 1991-738400	B2	19910731
			US 1992-916066	A	19920724
			WO 1992-US6318	A	19920729

OTHER SOURCE(S): MARPAT 121:195901
GI



I

AB Immunoassay methods and reagents for the quantification of total doxepins (i.e., E-doxepin, Z-doxepin, E-desmethyldoxepin, and Z-desmethyldoxepin) in a test sample are disclosed. The methodol. uses antibodies prepd. with immunogens I (YZ = NCH2, CH:CH, R1 = linking group with 1-6 C and 0-2 heteroatoms; R2 = H, Me; Q = immunogenic carrier) and labeled reagents I (YZ, R1, R2 as above; Q = detectable moiety). Prepn. of immunogens and labeled compds. is included. A fluorescence polarization immunoassay for total doxepins using the compds. of the invention is described; std. curves are included. There was a good correlation of the above assay with an HPLC assay.

IT **141990-98-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in reagent prepn. for total doxepin immunoassay)

RN 141990-98-9 CAPLUS
CN Carbamic acid, (3-dibenz[b,e][1,4]oxazepin-5(11H)-ylpropyl)methyl-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 23 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1993:472937 CAPLUS
DOCUMENT NUMBER:	119:72937
TITLE:	A new chromogenic beta-galactosidase substrate based on the redox indicator dye 'methyl purple'
AUTHOR(S):	Corey, Paul F.
CORPORATE SOURCE:	Diagn. Div., Miles Inc., Elkhart, IN, 46515, USA
SOURCE:	Bioorganic & Medicinal Chemistry Letters (1993), 3(2), 175-8

09/ 076,575

CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The .beta.-galactoside of 'methyl purple' I and II is a new chromogenic substrate that exhibits a 137 nm color shift upon hydrolysis at pH 7.4, a Km of 0.075 mM and a kcat of 1.2 .times. 104 mol min-1/mol of .beta.-galactosidase active site.

IT **50354-32-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(glycosidation of)

RN 50354-32-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy-11-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 24 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:205217 CAPLUS
DOCUMENT NUMBER: 118:205217
TITLE: Reagents and methods for the immunochemical quantification of total tricyclic antidepressant doxepins in biological fluids
INVENTOR(S): Adamczyk, Maciej; Fishpaugh, Jeffrey R.; Hruska, Robert E.; Johnson, Donald
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

09/ 076,575

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9303372	A1	19930218	WO 1992-US6318	19920729
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5332661	A	19940726	US 1992-916066	19920724
AU 9224206	A1	19930302	AU 1992-24206	19920729
EP 641440	A1	19950308	EP 1992-917171	19920729
EP 641440	B1	20001108		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 3071824	B2	20000731	JP 1993-503720	19920729
JP 06509797	T2	19941102		
AT 197508	E	20001111	AT 1992-917171	19920729

PRIORITY APPLN. INFO.: US 1991-738400 A 19910731
US 1992-916066 A 19920724
WO 1992-US6318 A 19920729

OTHER SOURCE(S): MARPAT 118:205217

AB Immunoassay methods and reagents are disclosed for the detn. of total doxepins (i.e. E-doxepin, Z-doxepin, E-demethyldoxepin, and Z-desmethyldoxepin) in a test sample. Doxpein derivs. contg. a conjugated immunogenic protein (for antibody prodn.) or a detectable label (for a tracer) are provided (Markush included). Prepn. of doxepin derivs. and their conjugation with albumin or reaction with e.g. aminomethylfluorescein are described. Antisera raised using the prepd. immunogens, as well as the prepd. tracers, were used in a fluorescence-polarization immunoassay for total doxepins (std. curves included). Linear regression anal. showed a good correlation between the assay of the invention and an HPLC assay.

IT **147392-99-2**
RL: ANST (Analytical study)
(as tracer for total doxepin immunoassay)

RN 147392-99-2 CAPLUS

CN Acetamide, 2-[(3-dibenz[b,e][1,4]oxazepin-5(11H)-ylpropyl)amino]-N-[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-4'-yl)methyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L8 ANSWER 25 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:168995 CAPLUS
DOCUMENT NUMBER: 118:168995
TITLE: Novel heterocyclic carboxylic acids
INVENTOR(S): Andersen, Knud Erik; Knutsen, Lars Jacob Stray; Soerensen, Per Olav; Lundt, Behrend Friedrich; Lau, Jesper; Petersen, Hans
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9220658		A1	19921126	WO 1992-DK155	19920514
	W: AU, BG, CA, CS, FI, HU, JP, KR, NO, PL, RO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2102811		AA	19921118	CA 1992-2102811	19920514
AU 9217837		A1	19921230	AU 1992-17837	19920514
AU 665761		B2	19960118		
EP 585314		A1	19940309	EP 1992-910899	19920514
EP 585314		B1	19960918		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507616		T2	19940901	JP 1992-509775	19920514
US 5348965		A	19940920	US 1992-882788	19920514
AT 143009		E	19961015	AT 1992-910899	19920514
ES 2094357		T3	19970116	ES 1992-910899	19920514
ZA 9203556		A	19930127	ZA 1992-3556	19920515
IL 101887		A1	19961016	IL 1992-101887	19920515
NO 9304159		A	19931117	NO 1993-4159	19931117

PRIORITY APPLN. INFO.: DK 1991-937 19910517
WO 1992-DK155 19920514

OTHER SOURCE(S): MARPAT 118:168995

GI



AB The title compd. I (A = B; R1, R2 = H, halo, F, C, C1-6-alkyl, -alkoxy; R4, R5 = H; R4R5 = direct bond; R6 = OH, C1-8-alkoxy; Y = >NCH2-, >CHCH2-, >C:CH-; Z = O, S, CH2, etc.; m, n, p-s = 0-4) (II) were prepd. by treating I (A = halo, p-toluenesulfonate, mesylate) with BH in the presence of an alkali metal iodide and K2CO3. II are useful in treating a central nervous system ailment related to GABA uptake.

IT **146844-18-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and GABA inhibition by)

RN 146844-18-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[2-[2-(6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)ethoxy]ethyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L8 ANSWER 26 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:426530 CAPLUS
DOCUMENT NUMBER: 117:26530
TITLE: Efficient synthesis of tricyclic antidepressant normetabolites.
AUTHOR(S): Adamczyk, Maciek; Fishpaugh, Jeffrey R.; Johnson, Donald
CORPORATE SOURCE: Abbott Lab., Abbott Park, IL, 60064, USA
SOURCE: Organic Preparations and Procedures International (1992), 24(2), 168-71
CODEN: OPPIAK; ISSN: 0030-4948
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:26530
GI



I

AB E- And Z-doxepins (I, X = C:CHCH2CH2NMe2) and dibenz[b,e][1,4]oxazepine I (X = NCH2CH2CH2NMe2) were N-demethylated by sequential treatment with Cl3CCH2OCOCl/EtN(CHMe2)2/CHCl3 and Zn/THF to give I (X = C:CHCH2CH2NHMe, NCH2CH2CH2NHMe), resp., via carbamates I (X = C:CHCH2CH2NMeCO2CH2CCl3, NCH2CH2CH2NMeCO2CH2CCl3).
IT **141990-98-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reductive deacylation of, with zinc)
RN 141990-98-9 CAPLUS
CN Carbamic acid, (3-dibenz[b,e][1,4]oxazepin-5(11H)-ylpropyl)methyl-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 27 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1991:247659 CAPLUS
DOCUMENT NUMBER: 114:247659
TITLE: Preparation of chromogenic hydroxydibenzoxazepinones and -dibenzothiazepiones, including their glycosides, as substrates for enzyme detection
INVENTOR(S): Corey, Paul F.
PATENT ASSIGNEE(S): Miles, Inc., USA
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 402699	A2	19901219	EP 1990-110198	19900530
EP 402699	A3	19910130		
EP 402699	B1	19950222		
R: DE, FR, GB, IT				
US 5104980	A	19920414	US 1989-364157	19890612
CA 2013525	AA	19901212	CA 1990-2013525	19900330
CA 2013525	C	19970304		
AU 9053967	A1	19910103	AU 1990-53967	19900426
AU 609008	B2	19910418		
JP 03041073	A2	19910221	JP 1990-150072	19900611
JP 3072350	B2	20000731		
DD 297965	A5	19920130	DD 1990-341536	19900611
US 5183743	A	19930202	US 1991-800112	19911129

PRIORITY APPLN. INFO.: US 1989-364157 A 19890612
OTHER SOURCE(S): MARPAT 114:247659
GI



I



II

AB The title compds. [I, II; Y = enzyme-cleavable group, e.g., glycosyl, acylglycosyl, acyl, (HO)2P(O); W = O, S; R, R1 = H, alkyl, aryl] were prepd. I [R = Me, R1 = Y = H, W = O] was glycosidated with acetobromogalactose in the presence of Ag2O in quinoline/AcOEt to give I [R = Me, R1 = H, W = O, Y = tetra-O-acetylgalactopyranosyl], which was sensitive enough to detect .beta.-galactosidase at 0.025 IU/mL.

09/ 076,575

IT **50354-32-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(glycosidation of)
RN 50354-32-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy-11-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 28 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1990:98410 CAPLUS
DOCUMENT NUMBER: 112:98410
TITLE: Dibenzoxocinamines and related compounds as antipsychotics
INVENTOR(S): Rae, Duncan Robertson; Cairns, James
PATENT ASSIGNEE(S): AKZO N. V., Neth.
SOURCE: Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 332246	A1	19890913	EP 1989-200473	19890227
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
ZA 8901625	A	19891129	ZA 1989-1625	19890302
FI 8901099	A	19890912	FI 1989-1099	19890308
US 4904688	A	19900227	US 1989-320340	19890308
DK 8901152	A	19890912	DK 1989-1152	19890309
JP 02004740	A2	19900109	JP 1989-57656	19890309
AU 8931205	A1	19890914	AU 1989-31205	19890310

PRIORITY APPLN. INFO.: EP 1988-302129 19880311
OTHER SOURCE(S): MARPAT 112:98410
GI



I



II

AB The title compds. (I; R1, R2 = H, OH, C1-6 alkyl, alkoxy, halo, CF3, CN; R3, R4 = H, C1-6 alkyl; R3R4N = 5- or 6-membered heterocyclyl; X = O, S, CH2, imino; m, n = 1-4), useful as antipsychotics devoid of extrapyramidal side effects (no data), were prepd. Thus, 5H-dibenz[b,g]oxocin-6(7H)-one (prepn. given) was refluxed 3 h in HCO2H/methylformamide contg. MgCl2.6H2O

to give 6,7-dihydro-N-methyl-5H-dibenz[b,g]oxocine-6-formamide. The latter was refluxed with EtOH/50% aq. NaOH for 18 h to give 6,7-dihydro-N-methyl-5H-dibenz[b,g]oxocin-6-amine, isolated as the HCl salt. The preferred I is oxocinamine II. I are said to be very potent dopamine and serotonin antagonists.

IT **125449-17-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antipsychotic)

RN 125449-17-4 CAPLUS

CN Dibenz[b,g]azocin-6-amine, 5,6,7,12-tetrahydro-N,12-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 29 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1988:640655 CAPLUS
DOCUMENT NUMBER: 109:240655
TITLE: Electrophotographic photoreceptor containing hydrazone charge-transporting material
INVENTOR(S): Hirose, Hisahiro; Kinoshita, Akira; Takei, Yoshiaki; Goto, Satoshi
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63186249	A2	19880801	JP 1987-17752	19870128

PRIORITY APPLN. INFO.: JP 1987-17752 19870128
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title electrophotog. photoreceptor has a layer contg. I [Y = bonding chain, unsubstituted methylene, (substituted) ethylene, (substituted) vinylene, (substituted) propylene; R1,R2 = (substituted) alkyl, (substituted) aryl, (substituted) aralkyl; R3-R10 = H, alkyl, alkoxy, OH, halogen; Ar1,Ar2 = (substituted) benzone ring; (substituted) polycondensed ring, (substituted) heterocyclic ring] as a charge-transporting material. The photoreceptor shows improved sensitivity, and durability. An

electrophotog. photoreceptor having a charge-generating layer contg. II and a charge-transporting layer contg. III showed the surface potential Va = 1250 V at the 1st measurement Va = 1190 V at the 100th measurement, and the exposure value E50500 = 7.0 lx-s at the 1st measurement and E50500 = 6.7 lx-s at the 100th measurement.

IT **117791-64-7**
RL: USES (Uses)
(charge-transporting material, electrophotog. photoreceptor contg.)

RN 117791-64-7 CAPLUS

CN Dibenz[b,g]azocin-12(5H)-amine, N-[3,3-bis[4-(dimethylamino)phenyl]-2-propenylidene]-6,7-dihydro- (9CI) (CA INDEX NAME)



L8 ANSWER 30 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1987:458829 CAPLUS

DOCUMENT NUMBER: 107:58829

TITLE: The chemistry of 5,6,7,12-tetrahydro-5,7-dioxo-N-phenyldibenz[b,g]azocine: a new entry in the dibenz[b,g]azocine class

AUTHOR(S): Fox, John L.; Chen, Chin H.; Luss, Henry R.

CORPORATE SOURCE: Corp. Res. Lab., Eastman Kodak Co., Rochester, NY, 14650, USA

SOURCE: Journal of Organic Chemistry (1987), 52(14), 2980-3
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 107:58829

GI



I

09/ 076,575

AB The title compd. I was isolated as a byproduct of methylating the sterically hindered 2,2'-dicarbomethoxytriphenylamine. The isolation, chem. and phys. characterization, and single-crystal x-ray structure of the title compd. are described. The structure and properties for several derivs. are also reported.

IT **108561-09-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and ring cleavage of)

RN 108561-09-7 CAPLUS

CN Benzoic acid, 2-(6,7-dihydro-5-hydroxy-5-methyl-7-methylenedibenz[b,g]azocin-12(5H)-yl)-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 31 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1987:458825 CAPLUS

DOCUMENT NUMBER: 107:58825

TITLE: Dibenzocyclooctene-, dibenzochalcocine-, and diarenochalconinediones

AUTHOR(S): Hellwinkel, Dieter; Bohnet, Siegbert

CORPORATE SOURCE: Org. Chem. Inst., Univ. Heidelberg, Heidelberg, D-6900/1, Fed. Rep. Ger.

SOURCE: Chemische Berichte (1987), 120(7), 1151-73
CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 107:58825

GI



I



II



III



IV

09/ 076,575

AB 2,2'-Oxybis-, -thiobis-, and -methylenebisbenzoic esters react with MeLi in ether to give low yields of 5H-dibenzo[b,g]chalcocine-5,7(6H)-diones I (X = O, S) and dibenzo[a,d]cyclooctene-5,7(6H,12H)-dione (I; X = CH2), resp. Very good yields of such heterocycles with oxygen, e.g., I (X = O), sulfur, e.g., I (X = S), and selenium I (X = Se) as key atoms are obtained when diaryl ethers, -sulfides, and -selenides that contain 2'-acetyl- (or-propionyl-) and 2-methoxycarbonyl groups are treated with NaH in boiling toluene. Analogously are prepd. the dibenz[b,g]oxonine-11,13(6H,12H)-diones II (R = H, Me, MeO) and 7H-benzo[h]naphtho[1,8-bc]thionine-7,9(8H)-dione (III), which are expanded by one ring member. In the analogous reaction of a corresponding benzophenone deriv. spiro[1H-indene-1,1'(3'H)-isobenzofuran]-3(2H),3'-dione (IV) is formed in a tandem reaction. Under phase transfer conditions the dibenzochalcocinediones and also the corresponding nitrogen cycles react to give mixts. of C- and O-alkyl derivs. With bromine and SO2Cl2, resp., the methylene group is mono- or dihalogenated to give the products.

IT **104014-54-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 104014-54-2 CAPLUS

CN Dibenz[b,g]azocin-5(12H)-one, 7-methoxy-12-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 32 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1987:4845 CAPLUS

DOCUMENT NUMBER: 106:4845

TITLE: 12-Organyldibenz[b,g]azocine-5,7-diones

AUTHOR(S): Hellwinkel, Dieter; Ittemann, Peter

CORPORATE SOURCE: Org.-Chem. Inst., Univ. Heidelberg, Heidelberg, 6900, Fed. Rep. Ger.

SOURCE: Chemische Berichte (1986), 119(10), 3165-97
CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 106:4845

GI



I

AB The title compds. I (R = Ph, substituted Ph, 1-naphthyl) and the p-phenylene dimer are formed in low yields on treatment of (2-MeO2CC6H4)2NR with MeLi, but in high yields in the intramol. ester condensation of 2-AcC6H4NRC6H4CO2Me-2 with NaH. I exist exclusively in the .beta.-diketo form and react with excess NaH or LiH to give the enolates. These, on treatment with MeI, form mixts. of C- and O-methylated derivs. Nucleophiles, such as NH2OH, arylhydrazines, MeLi, and also LiAlH4, condense or add to the carbonyl groups, whereas KOH-MeOH leads to ester or acid cleavage with ring opening. Electrophiles react predominantly at the N-aryl groups, but under more severe conditions also at the fused arenes. Strong acids, however, cause formal ketene extrusion and ring contraction, leading to acridones.

IT **104014-54-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 104014-54-2 CAPLUS

CN Dibenz[b,g]azocin-5(12H)-one, 7-methoxy-12-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 33 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1985:109297 CAPLUS

DOCUMENT NUMBER: 102:109297

TITLE: Methyl purple, an exceptionally sensitive monitor of chloroplast photosystem I turnover: physical properties and synthesis

AUTHOR(S): Graan, Thomas; Ort, Donald R.; Prince, Roger C.

CORPORATE SOURCE: Dep. Plant Biol., Univ. Illinois, Urbana, IL, 61801, USA

SOURCE: Analytical Biochemistry (1985), 144(1), 193-8
CODEN: ANBCA2; ISSN: 0003-2697

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The specific molar absorption coeffs. of both the anionic and protonated forms of Me purple were detd. The oxidn.-redn. midpoint potential of Me

purple over the pH range 3 to 12 was also detd. by polarog. methods, and the effect of pH on the visible absorption spectrum is reported. A detailed procedure for the synthesis of Me purple is given.

IT **50354-32-0P**
RL: PREP (Preparation)
(prepn. of, as sensitive monitor of chloroplast photosystem I turnover)

RN 50354-32-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy-11-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 34 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1983:470780 CAPLUS
DOCUMENT NUMBER: 99:70780
TITLE: Tricyclic ethers and their use in pharmaceutical preparations
INVENTOR(S): Malen, Charles; Poignant, Jean Claude
PATENT ASSIGNEE(S): ADIR, Fr.
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 74304	A1	19830316	EP 1982-401567	19820824
EP 74304	B1	19850403		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
FR 2512024	A1	19830304	FR 1981-16347	19810827
FR 2512024	B1	19840106		
US 4496557	A	19850129	US 1982-408451	19820816
CA 1227481	A1	19870929	CA 1982-409886	19820820
AT 12497	E	19850415	AT 1982-401567	19820824
ES 515232	A1	19831101	ES 1982-515232	19820825
AU 8287730	A1	19830303	AU 1982-87730	19820826
JP 58074673	A2	19830506	JP 1982-148452	19820826
JP 61029950	B4	19860710		
ZA 8206252	A	19830727	ZA 1982-6252	19820826
HU 30018	O	19840228	HU 1982-2756	19820826
IL 66650	A1	19850830	IL 1982-66650	19820826

PRIORITY APPLN. INFO.: FR 1981-16347 19810827
EP 1982-401567 19820824
OTHER SOURCE(S): CASREACT 99:70780
GI



I



II

AB Psychotropic (no data) cyclic ethers I (X = bond, CH2, NR4; R, R1 = H, halogen, alkyl, alkoxy, CF3; R2, R3 = H, alkyl; NR2R3 = heterocyclic; R4 = H, alkyl, acyl) were prepd. Thus the dibenzoxazepinone II (R3 = H, R5R6 = O) was N-acetylated and treated with MeO2CCH:PPh3 to give II (R3 = Ac, R5R6 = CHCO2Me) which was hydrogenated to II (R3 = Ac, R5 = H, R6 = CH2CO2Me). LiBEt3H redn. of the ester group gave II (R3 = Ac, R5 = H, R6 = CH2CH2OH) which was tosylated and treated with Me2NH to give II (R3 = Ac, R5 = H, R6 = CH2CH2NMe2).

IT **15676-55-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(acetylation of)

RN 15676-55-8 CAPLUS

CN Dibenz[b,e][1,4]oxazepin-11(5H)-one (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 35 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1983:414345 CAPLUS

DOCUMENT NUMBER: 99:14345

TITLE: 12-Phenyl-5,12-dihydrodibenz[b,g]azocin-5-one, C21H15NO

AUTHOR(S): Preut, Hans; Thimme, Michael; Eicher, Theophil; Krueger, Carl

CORPORATE SOURCE: Abt. Chem., Univ. Dortmund, Dortmund, D-4600, Fed. Rep. Ger.

SOURCE: Acta Crystallographica, Section C: Crystal Structure Communications (1983), C39(6), 768-70
CODEN: ACSCEE; ISSN: 0108-2701

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The title compd. is monoclinic, space group C2/c, with a 15.724(12), b 9.222(6), c 21.504(16) .ANG., and .beta. 95.91(8).degree.; Z = 8 for d = 1.274. Final R = 0.055 for 1170 data. The mol. structure has been elucidated at. coordinates are give.

IT **86156-66-3**
RL: PRP (Properties)
(structure of)

RN 86156-66-3 CAPLUS

CN Dibenz[b,g]azocin-5(12H)-one, 12-phenyl- (9CI) (CA INDEX NAME)



L8 ANSWER 36 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1982:217741 CAPLUS
DOCUMENT NUMBER: 96:217741
TITLE: Further studies on the reaction of N-(2-hydroxyphenyl)anthranilic acids with acetic anhydride
AUTHOR(S): Kim, Dong Han
CORPORATE SOURCE: Res. Div., Wyeth Lab. Inc., Philadelphia, PA, 19101, USA
SOURCE: Journal of Heterocyclic Chemistry (1981), 18(7), 1389-92
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II



III IV

AB The anthranilic acids I (R = H, R1 = H, Cl, R2 = H; R = NO2, R1 = H, R2 = Me; R = NO2, R1 = Me, R2 = H) reacted with Ac2O to give the benzoxazoloquinolinones II and various minor products, e.g. the benzoxazoloquinolinone III and dibenzoxazepinone IV.

IT **79091-34-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and acetylation of)

09/ 076,575

RN 79091-34-2 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-11(5H)-one, 8-methyl-2-nitro- (9CI) (CA INDEX NAME)



L8 ANSWER 37 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1981:532837 CAPLUS
DOCUMENT NUMBER: 95:132837
TITLE: Cyanogen bromide as a reagent for lactone formation. Preparation of dibenz[b,e][1,4]oxazepin-11(5H)-ones
AUTHOR(S): Kim, Dong Han
CORPORATE SOURCE: Res. Div., Wyeth Lab., Inc., Philadelphia, PA, 19101, USA
SOURCE: Journal of Heterocyclic Chemistry (1981), 18(4), 855-6
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II

AB The title compds. I (R-R2 = H; R = R2 = H, R1 = Cl; R = NO2, R1 = Me, R2 = H, R1 = H, R2 = Me) were prepd. in 52.5-83% yields by cyclizing II with BrCN in the presence of Et3N.
IT **15676-55-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 15676-55-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-11(5H)-one (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 38 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1976:490359 CAPLUS
DOCUMENT NUMBER: 85:90359
TITLE: Uncoupling of electron transport by anionic quinonoid redox indicator dyes
AUTHOR(S): Hill, R.; Crofts, A. R.; Prince, R. C.; Evans, E. Hilary; Good, N. E.; Walker, D. A.
CORPORATE SOURCE: Dep. Biochem., Univ. Cambridge, Cambridge, UK
SOURCE: New Phytologist (1976), 77(1), 1-9
CODEN: NEPHAV; ISSN: 0028-646X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III, R=H
IV, R=Me

AB A considerable range of oxidn.-redn. dyes (i.e. I .fwdarw. II) was studied with ref. to reactions with illuminated chloroplast prepns. Exptl. methods included dye-mediated H+- and H-transfer across liposome membranes, comparison of increase in the uncoupling properties with increase of substituting halogen atoms and effect of halogen substitution on distribution of anion between water and octanol. In the absence of halogen substitution a relatively high concn. of a dye was needed for significant uncoupling. Introduction of the sulfonic group NaSO3- abolished the uncoupling effect even in presence of halogen substitution.

IT **50354-31-9**
RL: BIOL (Biological study)
(in photosynthetic electron transport uncoupling)

RN 50354-31-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy- (9CI) (CA INDEX NAME)



L8 ANSWER 39 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1976:69236 CAPLUS
DOCUMENT NUMBER: 84:69236

09/ 076,575

TITLE: Basic derivatives of 6,7-dihydroindolo[1,7-ab][1]benzazepine and 6H-indolo[7,1-cd][1,5]benzoxazepine as potential antidepressant agents
AUTHOR(S): Toscano, Luciano; Grisanti, Giampiero; Fioriello, Giuseppe; Seghetti, Ennio; Bianchetti, Alberto; Bossoni, Giuseppe; Riva, Mario
CORPORATE SOURCE: Res. Lab., Pierrel S.p.A., Milan, Italy
SOURCE: Journal of Medicinal Chemistry (1976), 19(2), 208-13
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Of 14 title compds. prepd. and screened for antidepressant activity in mice 1-[2-(benzylmethylamino)ethyl]-6,7-dihydroindolo[1,7-ab][1]benzazepine-HCl (I) [57529-83-6] and 1-[2-(methylamino)ethyl]-6,7-dihydroindolo[1,7-ab][1]benzazepine-HCl (II) [57529-85-8] had the best activity profiles. I was as active as imipramine [50-49-7] in antagonizing serotonin-induced contraction of the isolated guinea-pig ileum. With few exceptions, the compds. not substituted at position 2 antagonized reserpine-induced ptosis and hypothermia, showing negligible anticholinergic and antihistaminic properties.
IT **57529-61-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Fischer cyclization reaction with keto compds.)
RN 57529-61-0 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-5(11H)-amine, monohydrochloride (9CI) (CA INDEX NAME)



⊕ HCl

L8 ANSWER 40 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1975:455770 CAPLUS
DOCUMENT NUMBER: 83:55770
TITLE: Reduction of artificial electron acceptors at subzero temperatures by chloroplasts suspended in fluid media
AUTHOR(S): Cox, Raymond P.
CORPORATE SOURCE: Inst. Biol. Phys.-Chim., Paris, Fr.
SOURCE: Biochimica et Biophysica Acta (1975), 387(3), 588-98
CODEN: BBACAQ; ISSN: 0006-3002
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Chloroplasts ca be suspended in aq./org. mixts. which are liq. at sub-zero temps. with a good retention of the ability to reduce artificial electron acceptors. The redn. of ferricyanide and 2,6-dichlorophenolindophenol at temps. >0.degree. is .apprx.50% inhibited by 50% (vol./vol.) ethylene glycol. Higher concns. cause more extensive inhibition. Different solvents were compared on the basis of their ability to cause a given depression of the freezing point of an aq. soln. Ethylene glycol caused less inhibition of electron transport than glycerol, which in its turn was

found to be superior to MeOH. The redn. of oxidized 2,3,5,6-tetramethyl-p-phenylenediamine could be measured at -25.degree. in 40% (vol./vol.) ethylene glycol. Using an acceptor with a high extinction coeff., methyl purple (a deriv. of 2,6-dichlorophenolindophenol) it was possible to obs. electron flow at temps. as low as -40.degree. in 50% (vol./vol.) ethylene glycol. From studies of the effects of the inhibitors 3(3,4-dichlorophenyl)-1,1-dimethylurea and 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone it is suggested that electron flow from the donor side of photosystem II to the acceptor side of photosystem I can occur at temps. at least as low as -25.degree.. The ultimate electron donor is presumably water but it was not possible to demonstrate this directly.

IT **50354-32-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(photoredn. of, by chloroplast, org. solvent and temp. effects on)

RN 50354-32-0 CAPLUS

CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy-11-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 41 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1975:81187 CAPLUS

DOCUMENT NUMBER: 82:81187

TITLE: Effect of substituted dibenzoxazepines on levels of reduced glutathione and potassium ions in lenses of rabbits in vitro and of rats in vivo

AUTHOR(S): Wong, Keith K.; Wang, Geng Mei; Dreyfuss, Jacques; Schreiber, Eric C.

CORPORATE SOURCE: Dep. Drug Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA

SOURCE: Journal of Pharmaceutical Sciences (1974), 63(6), 854-7
CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Substituted dibenzoxazepines decreased the levels of K+ [7440-09-7] and reduced glutathione (GSH) [70-18-8] in isolated rabbit lenses, the effects of some of the compds. correlating with their tendency to bind to erythrocyte ghosts. The dietary administration of substituted dibenzoxazepines to rats also lowered GSH levels in lenses, the response being greatest in those animals that showed the most severe morphol. changes. Measurement of GSH and K+ levels in lenses may aid in preliminary detn. of the cataractogenicity of the dibenzoxazepines. 4-[3-(7-Chloro-5,11-dihydrodibenz[b,e][1,4]oxazepin-5-yl)propyl]-1-piperazineethanol-HCl (I) [**41296-98-4**] caused the greatest decrease in GSH and K+ of isolated lenses.

IT **27139-87-3**
RL: PRP (Properties)
(potassium and reduced glutathione of eye in response to)

RN 27139-87-3 CAPLUS

CN 1-Piperazineethanol, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 42 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1974:477985 CAPLUS
DOCUMENT NUMBER: 81:77985
TITLE: N-Oxides of 5-(aminoalkyl)-5,11-dihydrodibenzoxazepines and 5,11-dihydrodibenzthiazepines
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3796725	A	19740312	US 1971-110327	19710127
PRIORITY APPLN. INFO.:			US 1969-655352	19690724
			US 1970-17966	19700309

AB The title compds., e.g. I (R = R1 = Me, HOCH2CH2; RR1 = (CH2)4, CH2CH2OCH2CH2, CH2CHMeCH2CH2; R2 = H, Me; n = 1,2,3; X = O, S) and II(R = H, F3C; X = O, S) were prepd. by oxidn. of the corresponding amines. Thus, 5,11-dihydrobenz[b,e] [1,4] oxazepine was treated with Br(CH2)3Cl followed by (HOCH2CH2)2NH to give 5,11-dihydro-5-[3-[bis(2-hydroxyethyl)amino]propyl]dibenz[b,e] [1,4]oxazepine which was oxidized with 30% HiO2 to give I [R = R1 = HOCH2CH2, R2 = H, X = O, n = 3). At 5-50 mg/kg I and II were antiarrhythmic. At 0.001-0.1% I and II eliminated S. aureus and T. mentagrophytes.

IT **27488-77-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 27488-77-3 CAPLUS
CN 1-Piperazineethanol, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]-, (2Z)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 27139-87-3
CMF C23 H28 F3 N3 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L8 ANSWER 43 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1974:121023 CAPLUS
DOCUMENT NUMBER: 80:121023
TITLE: N-[3-(5,11-Dihydrodibenzo[b,e][1,4]thia- and -oxazepin-5-yl)phthalamides
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Brit., 2 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1343923	A	19740116	GB 1973-33769	19710223

PRIORITY APPLN. INFO.: GB 1973-33769 19710223
GI For diagram(s), see printed CA Issue.
AB Title compds. (I; X = S, R = H; X = O, R = CF3) were prepd. by refluxing in DMF K phthalimide and the corresponding 3-(chloropropyl)dibenzothiazepine or -oxazepine obtained by treating DMF solns. of the appropriate dibenzothiazepine or -oxaze-pine with NaOH and Cl(CH2)3Br.
IT **28737-95-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 28737-95-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 44 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1974:83090 CAPLUS
DOCUMENT NUMBER: 80:83090
TITLE: 1-[3-(5,11-Dihydrodibenz[b,e][1,4]oxazepin-5-yl)propyl]phenylpiperidinols
INVENTOR(S): Yale, Harry L.
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3780044	A	19731218	US 1972-291422	19720922

PRIORITY APPLN. INFO.: US 1972-291422 19720922
GI For diagram(s), see printed CA Issue.
AB Antibacterial tuberculostatic dibenzoxazepines I (R = CF3, R1 = H; R = H, R1 = Cl) were prepd. Thus, 11.2 g (5,11-dihydro-7-trifluoromethyldibenz[b,e][1,4]oxazepin-5-yl)propyl chloride was treated with 7 g 4-phenyl-4-piperidinol to give .apprx.4 g I (R = CF3, R1 = H).
IT **51856-01-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 51856-01-0 CAPLUS
CN 4-Piperidinol, 4-phenyl-1-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 45 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

09/ 076,575

ACCESSION NUMBER: 1974:83089 CAPLUS
DOCUMENT NUMBER: 80:83089
TITLE: Dibenzoxazepines and dibenzothiazepines
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: U.S., 10 pp. Continuation-in-part of U. S. 3,657,275 (CA 77;34606g).
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3780059	A	19731218	US 1971-172569	19710817
US 3657275	A	19720418	US 1970-17972	19700309

PRIORITY APPLN. INFO.: US 1966-551560 19660520
US 1970-17972 19700309

GI For diagram(s), see printed CA Issue.

AB The title compds. and analogs I (n = 0, 1, m = 2, 3, R2 = guanidino, methylguanidino, phthalimido) and some [1,5]oxazocine and [1,5]-thiazocine analogs, useful as tranquilizers and sedatives were prepd. Thus, 5,11-dihydrodibenzo[b,e][1,4]thiazepine in DMF contg. NaH is treated with Br(CH2)3Cl to give I [n = 0, m = 3, R = R1 = H, Z = S, R2 = Cl). Reaction of this with K phthalimide in DMF yields I (R2 = phthalimido). An addnl. 49 examples are described.

IT **28737-95-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 28737-95-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 46 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1973:488982 CAPLUS
DOCUMENT NUMBER: 79:88982
TITLE: Old and some possible new redox indicators
AUTHOR(S): Hill, Robert
CORPORATE SOURCE: Dep. Biochem., Univ. Cambridge, Cambridge, UK
SOURCE: Journal of Bioenergetics (1973), 4(1-2), 229-37
CODEN: JBEGAA; ISSN: 0449-5705
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Some properties of redox indicators as developed from a study of the Liebermann nitroso reaction for phenols are described. Consideration of the effects of completing a hetero 6-membered ring, as in the azine, thiazine, and oxazine classes, is suggested for the development of redox indicators that would perhaps be more desirable than the indophenols.

09/ 076,575

IT **50354-31-9**
RL: PRP (Properties)
(NMR of)
RN 50354-31-9 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-2(11H)-one, 8-hydroxy- (9CI) (CA INDEX NAME)



L8 ANSWER 47 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1973:442582 CAPLUS
DOCUMENT NUMBER: 79:42582
TITLE: Dibenzoxazepines and dibenzothiazepines
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: U.S., 12 pp. Division of U.S. 3,657,275 (CA 77;34606g).
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3723463	A	19730327	US 1971-172570	19710817
US 3657275	A	19720418	US 1970-17972	19700309

PRIORITY APPLN. INFO.: US 1966-551560 19660520
US 1970-17972 19700309

GI For diagram(s), see printed CA Issue.
AB The title compds. and higher ring analogs (I, R = H, Me, Pr; R1 = H, Me, Et; R2 = Br, Cl, CF3; Q = O, S; k = 2, 3; l, m, n = 0, 1, 2; X = HCl, 0.5H2SO4) were prepd. Thus, 5,11-dihydrodibenz[b,e][1,4]oxazepine-5-propionitrile was hydrolyzed with H2SO4 and the resulting amide reduced with LiAlH4 to give 5,11-dihydrodibenz[b,e][1,4]oxazepine-5-propylamine, which was treated with 2-methyl-2-thiopseudourea sulfate to give I (R = R1 = R2 = H, k = 3, l = m = 0, n = 1, Q = O, X = 0.5H2SO4). At 20-200 mg/day I were sedatives and hypotensive agents.
IT **28737-95-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 28737-95-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 48 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1973:413382 CAPLUS
DOCUMENT NUMBER: 79:13382
TITLE: Distribution of dibenzoxazepines bearing the carboxamide or other side chains in ocular and other tissues of dogs
AUTHOR(S): Dreyfuss, Jacques; Shaw, James M.; Ross, John J., Jr.; Wang, Geng Mei; Wong, Keith K.; Schreiber, Eric C.
CORPORATE SOURCE: Dep. Drug. Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA
SOURCE: Journal of Pharmaceutical Sciences (1973), 62(4), 606-9
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English

AB After oral or i.v. administration of labeled [4-[3-(7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepin-5-yl)propyl]-1-piperazinyl]ethanol-HCl [**40671-55-4**], its trifluoromethyl analog, or 5-[2-(dimethylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine maleate [19625-12-8] to dogs, greater concns. of radioactivity were found in the organs, esp. the brain, liver, lungs, and melanin-contg. portions of the eye, than in the blood. The same compds. were bound to various extents to melanin granules of beef eyeball in vitro. However, 7-chloro-5,11-dihydrodibenz[b,e][1,4]oxazepine-5-carboxamide (I) [16802-77-0] was neither localized in any tissues of the dog, relative to concns. in the blood, nor bound to melanin granules in vitro. Thus, the presence of the carboxamide side chain alters I affinity for tissues, esp. those contg. melanin.

IT **41241-23-0**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metab. of, by eye and other tissues)
RN 41241-23-0 CAPLUS
CN 1-Piperazineethanol, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 49 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1973:111389 CAPLUS

09/ 076,575

DOCUMENT NUMBER: 78:111389
TITLE: 5,11-Dihydrodibenzoxazepines derivatives
INVENTOR(S): Yale, Harry L.; Sowinski, Frances A.
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3714192	A	19730130	US 1970-76285	19700928

PRIORITY APPLN. INFO.: US 1965-438406 19650309
US 1967-668632 19670918

GI For diagram(s), see printed CA Issue.

AB (Anilinobenzyl)dihydrodibenzoxazepine I (R = Me2NCH2CH2) and its salts, which possess hypotensive, antibacterial, antifungal, and tumor inhibition activity, was prepd. by reaction of dihydrodibenzoxazepine II (R = Me2NCH2CH2) with excess NaH and 2 equivs. Me2NCH2CH2Cl in refluxing THF.

IT **16882-84-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 16882-84-1 CAPLUS

CN 1,2-Ethanediamine, N-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)phenyl]-N-[2-[2-(dimethylamino)ethoxy]phenyl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 50 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1973:97735 CAPLUS
DOCUMENT NUMBER: 78:97735
TITLE: Dibenzoxazepines and dibenzothiazepines
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Fr. Demande, 26 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2128097	A5	19721020	FR 1971-7494	19710304

FR 2128097 B1 19740802
PRIORITY APPLN. INFO.: FR 1971-7494 19710304
GI For diagram(s), see printed CA Issue.
AB Approx. 25 guanidines [I, R = (CH2)nNR1C(:NH)NHR2 n = 0-4, R1 = H, Me, Et, etc.; R2 = H, Me; X = O, S; x, y, z = 0-2; R3 = Cl, Br, H, CF3] were prepd. from I[R = (CH2)nNHR1] and RNHC(:NH)SR5.H2SO4 (R5 = H, Me). Some of the guanidines prepd. were 1-[3-(2-chloro-11,-12-dihydro-6H-dibenzo[b,f][1,4]thiazocin-12-yl)-propyl]-3-methylguanidine [I, R = (CH2)3NHC(:NH)NHMe, X = S, x = z = 1, y = 0, R3 = Cl], 1-[3-(5,11-dihydro-7-(trifluoromethyl)dibenz[b,e][1,4]-oxazepin-5-yl)propyl]guanidine [I, R = (CH2)3NH(:NH)NH2, X = O, x = y = 0, z = 1, R3 = CF3], 1-[2-(10,12-dihydro-5H-dibenz-[c,f][1,5]oxazocin-5-yl)ethyl]-1-methylguanidine [R = CH2CH2NMeC(:NH)NH2, X = O, x = 0, y = z = 1, R3 = H], 1-benzyl-3-[3-(5,10,12,13-tetrahydrodibenzo[c,f][1,5]thiazonin-5-yl)-propyl]guanidine [I, R = (CH2)3N(CH2Ph)C(:NH)NH2, X = S, x = 0, y = 1, z = 2, R = H].
IT **28737-95-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 28737-95-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 51 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:564782 CAPLUS
DOCUMENT NUMBER: 77:164782
TITLE: Guanidine derivatives of condensed heterocycles
INVENTOR(S): Yale, Harry Louis; Bernstein, Jack
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger. Offen., 31 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2107669	A	19720831	DE 1971-2107669	19710217

PRIORITY APPLN. INFO.: DE 1971-2107669 19710217
GI For diagram(s), see printed CA Issue.
AB Guanidine derivs. I (n = 2,3; x and y = 0,1; X = O, S; R = H, Me, Pr, CH2Ph; and which may be substituted in one of the benzene rings by Cl, Br, or CF3) were prepd. Thus, 5,11-dihydrodibenzo [b,e] [1,4]-oxazepin-5-propionitrile was reduced to the propylamine with LiAlH4 and treated with MeSC(:NH)NH2 to give I (n = 3, x = 0, y = 1, X = O, R = H).
IT **28737-95-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(guanidine from)

09/ 076,575

RN 28737-95-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 52 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:539590 CAPLUS
DOCUMENT NUMBER: 77:139590
TITLE: Formylation of amines
INVENTOR(S): Yale, Harry Louis
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2209853	A	19720907	DE 1972-2209853	19720301
CA 948195	A1	19740528	CA 1972-135459	19720224
GB 1388917	A	19750326	GB 1972-9109	19720228
CH 540228	A	19730928	CH 1972-2904	19720229
FR 2127896	A5	19721013	FR 1972-7062	19720301

PRIORITY APPLN. INFO.: US 1971-119910 19710301

AB Primary and secondary amines, e.g. anilines, piperidines, or piperazines, were formylated in quant. yield by reaction with HCO2Ph (I) or HCO2C6H4Me-o. Thus, reaction of I with o-BrC6H4NH2 in PhOH at <20-5.degree. gave quant. o-BrC6H4NHCHO.

IT **38272-89-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 38272-89-8 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 53 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:501692 CAPLUS
DOCUMENT NUMBER: 77:101692
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzoxazepine and 5,11-dihydrodibenzothiazepine N-oxides with antibacterial and antiarryhthmic activity
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Fr. Demande, 12 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2085631	B1	19730608	FR 1970-12720	19700408

PRIORITY APPLN. INFO.: FR 1970-12720 19700408
GI For diagram(s), see printed CA Issue.
AB The dibenzoxazepines (I, R = H, CF3; R1 = N(O)Me2, 1-methyl-3-piperidyl, Cl, 4-(2-hydroxyethyl)-1-piperazinyl; n = 1-3) were prepd. Thus I (R = H, R1 = 1-methyl-3-piperidyl, n = 1) was obtained by treating 5,11-dihydrodibenzo[b,e] [1,4]oxazepine with (1-methyl-3-piperidyl)-methyl chloride in the presence of NaH. I (R = H, R1 = N(O)Me2, n = 2) was obtained by H2O2 oxidn. of I (R = H, R1 = NMe2, n = 2).
IT **27488-77-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 27488-77-3 CAPLUS
CN 1-Piperazineethanol, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]-, (2Z)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 27139-87-3
CMF C23 H28 F3 N3 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L8 ANSWER 54 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:488558 CAPLUS
DOCUMENT NUMBER: 77:88558
TITLE: 5,11-Dihydrodibenz[b,e][1,4]oxazepine- and -thiazepine-5-alkanoic acid derivatives
INVENTOR(S): Yale, Harry Louis; Petigara, Ramesh Balubhai
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger. Offen., 71 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2158327	A	19720531	DE 1971-2158327	19711124
US 3714201	A	19730130	US 1970-92498	19701124
US 3766210	A	19731016	US 1970-92329	19701124
CA 981666	A1	19760113	CA 1971-127969	19711118
CH 546786	A	19740315	CH 1971-16997	19711123
CH 551442	A	19740715	CH 1973-807	19711123
GB 1382586	A	19750205	GB 1971-54465	19711123
FR 2115385	A5	19720707	FR 1971-42131	19711124
FR 2115385	B1	19751010		
HU 163353	P	19730728	HU 1971-SU690	19711124

PRIORITY APPLN. INFO.: US 1970-92329 19701124
US 1970-92498 19701124

AB Nine title compds. (I, X = O, S, SO, SO2, n = 1-3, m = 0, 1, R = R1 = Et, R = Et2N(CH2)2, R1 = H, NRR1 = 4-methyl-1-piperazinyl,

4-(2-hydroxyethyl)-1-piperazinyl, morpholino; R2 = H, CF3, R3 = F3C, Cl), hypotensives, were prepd. by esterification of the acid or the acid chloride (II) and (in the case of X = S) intermediate S-oxidn. Thus, II (n = 2, R2 = H, R3 = F3C) (obtained by reaction of the N-unsubstituted compd. with H2C:CHCN, conversion into the Me ester, and chlorination with PCl5) was added to Et2N(CH2)2OH in CHCl3 and refluxed 3 hr to give, after addn. of oxalic acid, I oxalate (n = 2, m = 1, R = R1 = Et, R2 = H, R3 = F3C).

IT **37945-20-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 37945-20-3 CAPLUS

CN 1-Piperazineethanol, 4-[1-oxo-3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 47703-45-7
CMF C23 H26 F3 N3 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L8 ANSWER 55 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:434606 CAPLUS
DOCUMENT NUMBER: 77:34606
TITLE: Dibenzoxazepines and dibenzothiazepines
INVENTOR(S): Yale, Harry L.; Bernstein, Jack

09/ 076,575

PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3657275	A	19720418	US 1970-17972	19700309
US 3723463	A	19730327	US 1971-172570	19710817
US 3780059	A	19731218	US 1971-172569	19710817

PRIORITY APPLN. INFO.: US 1966-551560 19660520
US 1970-17972 19700309

GI For diagram(s), see printed CA Issue.

AB The title compds. and higher ring analogs (I, = H, Pr; R1 = H, Me, Et; R2 = Br, Cl, CF3; Q = O, S; X = HCl, 1/2H2SO4; k = 2,3; 1, m, n = 0.1) were prepd. Thus, 5,11-dihydrodibenz[b,e][1,4]oxazepine-5-propionitrile was hydrolyzed by H2SO4 and the resulting amide was reduced by LiAlH4 to 5,11-dihydrodibenz[b,e][1,4]oxazepine-5-propylamine, which, on treatment with 2-methyl-2-thiopseudourea sulfate, gave I (R = R1 = R2 = H, k = 3, 1 = m = 0, n = 1, Q = O, X = 1/2H2SO4). Nine other I were prepd. by known reactions.

IT **28737-95-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 28737-95-3 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 56 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:428740 CAPLUS
DOCUMENT NUMBER: 77:28740
TITLE: Species differences in the metabolism of a tricyclic psychotropic agent, SQ 11,290-14C
AUTHOR(S): Dreyfuss, Jacques; Shekosky, James M.; Ross, John J., Jr.; Schreiber, Eric C.
CORPORATE SOURCE: Dep. Drug Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA
SOURCE: Toxicology and Applied Pharmacology (1972), 22(1), 105-14
CODEN: TXAPA9; ISSN: 0041-008X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Following oral administration of 14C-labeled SQ 11,290 (4-[3-(7-chloro-5,11-dihydrodibenz[b,e]-[1,4]-oxazepin-5-yl)propyl]-1-piperazineethanol dihydrochloride)(I) [**28318-18-5**] to mice, rats, guinea pigs, hamsters, rabbits, monkeys, and man less than 1% of the

radioactivity excreted by any species was unchanged I. Radioactivity was excreted primarily in the feces of all species except hamsters and man in which urinary excretion was predominate.

IT **28318-18-5**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of, species in relation to)

RN 28318-18-5 CAPLUS

CN 1-Piperazineethanol, 4-[3-(7-chlorodibenz[b,e][1,4]oxazepin-5(11H)-yl)propyl]- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 57 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:127032 CAPLUS
DOCUMENT NUMBER: 76:127032
TITLE: 5,11-Dihydrodibenz[b,e][1,4]oxazepine derivatives
INVENTOR(S): Yale, Harry L.
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3631052	A	19711228	US 1970-10982	19700212

PRIORITY APPLN. INFO.: US 1970-10982 19700212

GI For diagram(s), see printed CA Issue.

AB Antianxiety title compds. (I) were prepd. NaOMe-EtOH was added dropwise to a mixt. of 5-trifluoromethyl-2-hydroxyformanilide and 4-chloro-2-bromobenzyl bro mide in EtOH to give 2-(4-chloro-2-bromobenzyloxy)-5-tri-fluoromethylformanilide (II). A mixt. of II, DMF, K2CO3, and copper bronze was heated 3.5 hr. to give 3-chloro-5,11-dihydro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepine - 5 - carboxaldehyde, from which the formyl group was removed by reflux with 25% aq. NaOH to give 3-chloro-5,11-dihydro-7-(trifluoromethyl)dibenz-[b,e][1.4]oxazepine (III). A mixt. of III, 2-[2-[2-(dimethylamino)ethyl]piperidino]ethyl chloride-HBr, AcEt, and NaOH was refluxed 3 hr to give I (R = Cl, R1 = 2-[2-(dimethylamino)-ethyl]piperidino, n = 2). Similarly prepd. was I [R = H, R1 = 4-(2-tetrahydropyranyloxy), n = 4] which, treated with conc. HCl gave I (R = H, R1 = OH, n = 4), which, treated with SOCl2 gave I (R = H, R1 = Cl, n = 4), which, refluxed 18 hr with 3-(2-aminobutyl)piperidine, NaI, and AcEt gave I [R = H, R1 = 3-(2-aminobutyl)piperidine, n = 4]. I

(R = H, R1 = 4-(aminomethyl)piperidino, n = 3) was similarly prepd.

IT **28713-84-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 28713-84-0 CAPLUS

CN 4-Piperidinemethanamine, 1-[3-[5,11-dihydro-7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5-yl]propyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 28770-42-5
CMF C23 H28 F3 N3 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L8 ANSWER 58 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:14605 CAPLUS
DOCUMENT NUMBER: 76:14605
TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenz[b,e][1,4]oxazepine and -thiazepine N-oxides and their acid addition salts
INVENTOR(S): Yale, Harry L.; Bernstein, Jack
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

09/ 076,575

DE 2016356 A 19711028 DE 1970-2016356 19700406
PRIORITY APPLN. INFO.: DE 1970-2016356 19700406
GI For diagram(s), see printed CA Issue.
AB I and their salts were prepd. Thus, 5-[2-dimethylamino)ethyl]-5,11-dihydrodibenz[b,e][1,4]oxazepine was refluxed 3.5 hr with 30% H2O2 in 95% EtOH to give I [R = (CH2)2N(O)Me2, R1 = H], which was treated with maleic acid in Me2CO to give the corresponding maleate. Similarly prepd. were several other I, including I [R = 3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl, R1 = CF3], its N-oxide, and N-oxide dimaleate.
IT **35019-32-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidn. and esterification of)
RN 35019-32-0 CAPLUS
CN 1-Piperazineethanol, 4-[3-[3-(trifluoromethyl)dibenz[b,e][1,4]-oxazepin-5(11H)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 59 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1971:517073 CAPLUS
DOCUMENT NUMBER: 75:117073
TITLE: Metabolism in dogs of the chloro- and trifluoromethyl analogs of a piperazine-substituted dihydrobenzoxazepine
AUTHOR(S): Dreyfuss, J.; Ross, J. J., Jr.; Shekosky, J. M.; Schreiber, E. C.
CORPORATE SOURCE: Dep. Drug Metab., Squibb Inst. Med. Res., New Brunswick, NJ, USA
SOURCE: Xenobiotica (1971), 1(1), 29-41
CODEN: XENOBH; ISSN: 0049-8254
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB After administration of [4-[3-[7-(chloro or trifluoromethyl)-5,11-dihydrobenz[b,e][1,4]oxazepin-5-yl]-1-piperazine-[14C2]-ethanol-2HCl) (SQ 11290-14C, or SQ 11005-14C, resp.) (I and II), the compds. were similarly excreted in urine and feces or bile. Highest concns. of radioactivity were found in the lungs, liver, and the ocular layers consisting of the combined retina, choroid, and sclera. Similar blood levels were found in dogs that had received equiv. doses. Unchanged SQ 11005 (5%) or SQ 11290 (8%) was present in the feces, the main excretory route. The major metabolite, a monooxygenated deriv. of the tricyclic ring system, was present in the feces and as glucuronide conjugate in the bile. The glucuronide conjugates of both parent compds. were excreted in the bile. Thus, chloro or trifluoromethyl substitution in the 7-position of the dihydrobenzoxazepine ring system did not alter the biol. disposition of

these mols. in the dog.

IT **27139-88-4**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of)

RN 27139-88-4 CAPLUS

CN 1-Piperazineethanol, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

L8 ANSWER 60 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1970:445482 CAPLUS

DOCUMENT NUMBER: 73:45482

TITLE: Novel polycyclic heterocycles. Derivatives of 5,11-dihydrodibenz[b,e][1,4]oxazepine and 5,11-dihydrodibenzo[b,e][1,4]thiazepine

AUTHOR(S): Yale, Harry L.; Beer, Bernard; Pluscec, Jelka; Spitzmiller, Erwin R.

CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ, USA

SOURCE: Journal of Medicinal Chemistry (1970), 13(4), 713-22
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB 5-Substituted 5,11-dihydrodibenz[b,c][1,4]oxazepines (e.g. I) and 5,11-dihydrodibenzo[b,e][1,4]thiazepines were prepd. When the 5-substituent is 3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl and a substituent like Cl or CF3 is in the 3 or 7 position, the compounds show antianxiety effects at lower doses and central nervous system depressant activity at higher doses. When the 5 substituent is a simple dialkylaminoalkyl group, the compounds are not depressants at either dose level, but instead are stimulants, but only at the higher dose range.

IT **27139-88-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. activity of)

RN 27139-88-4 CAPLUS

CN 1-Piperazineethanol, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11H)-yl]propyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

L8 ANSWER 61 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1970:111528 CAPLUS
DOCUMENT NUMBER: 72:111528
TITLE: 5-Piperazinopropyl-5,11-dihydrodibenz[b,e][1,4]oxazepines as ataractics and tranquilizers
INVENTOR(S): Yale, Harry L.
PATENT ASSIGNEE(S): Squibb, E. R., and Sons, Inc.
SOURCE: Ger. Offen., 25 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1944335	A	19700319	DE 1970-1944335	19700318
NL 6913679	A	19700313	NL 1969-13679	19690909
BE 738737	A	19700311	BE 1969-738737	19690911
FR 2017843	A1	19700522	FR 1969-30984	19690911

PRIORITY APPLN. INFO.: US 1968-759244 19680911
GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepd. via II [R2 = (CH2)3Cl] by reactio n with 2-(1-piperazinyl)ethanol (III). Thus, 400 g 3,4-O2NClC6H3CF3 was added to 300 g KOH in 2 l. Me OH and stirred 1 hr at room temp. to give 371 g 3,4-O2N(MeO)C6H3C F3, m. 46.5-48.0.degree., which (513 g) was hydrolyzed in 693 g pyridine-HCl at 155-60.degree. to give 3,4-O2N(HO)C6H3CF3 (IV), b13 96-100.degree.. IV (66 g) was hydrogenated over Pd-C and 94 ml 98-100% HCO2H added to give 55.3 g 4,3-HO(CHONH)C6H3CF3 (V), m. 172-3.degree.. NaOMe (69.8 g) in 750 ml EtOH was added to 265 g V, 324 g o-BrC6H 4CH2Br, and 2600 ml EtOH to give 347 g o-BrC6H4CH2OC6H3(N hCHO)CF3-2,4 (VI), m. 152-5.degree.. Simi-larly prepd. was 383 g 2,4-BrClC6H3CH2OC6H3(NHCHO)CF3-2,4. VI 5.6, K2CO3 9.5 and Cu powder 0.4 g and 100 ml Dow-therm was heated at 160-5.degree. to give 3.24 g II (R = Me, R1 = H, R2 = CHO), m. 130-2.degree., which was hydrolyzed by refluxing with 1560 ml 95% EtOH and 312 ml 25% NaOH to give 2.85 g II (R = CF3, R1 = R2 = H) (IIa), m. 1 18 20.degree.. Similarly prepd. was II (R = CF3, R1 = Cl, R2 = H), m. 135-7.degree.. IIa 62.5, Cl(CH2)3Br 150, and NaOH 75 g with 625 ml EtCOMe was re-fluxed 18 hr to give II [R = CF3, R1 = H, R2 = (CH2)3Cl] (IIb), m. 73-6.degree.. Similarly prepd. were the following II

[R2 = (CH2)3-Cl] (R, R1, and m.p. given): Cl, H, -; H, Cl, 70-3.degree.; CF3, Cl, -. IIb 50, III 34, and NaI 19 g, with 300 ml EtCOMe was refluxed 18 hr to give I (R = CF3, R1 = R2 = H) (Ia) b0.5 240.degree.; dihydrochloride m. 197-200.degree.; dimaleate m. 158-61.degree. (decompn.); dicitrate m. 110-14.degree. (decompn.); dipamoinate m. 162-4.degree.. Similarly prepd. were I (R2 = H) (R, R1, m.p., and m.p. salts given): Cl, H, (Ib) 91-3.degree., dihydrochloride m. 223-4.degree., dimaleate m. 171-3.degree.; H, Cl, -, dihydrochloride m. 229-32.degree., dimaleate m. 168-71.degree.; CF3, Cl, b0.cntdot.1 260.degree., -. n-C6H13COCl (4.5 g) in 50 ml C6H6 and 8.0 g Ib in 120 ml C6H6 was heated 3 hr at 75.degree. to give I (R = Cl, R1 = H, R2 = COC6H13-n); dimaleate m. 171-2. Similarly prepd. were I (R = Cl, R1 = H) (R2 and m.p. dimaleate given): COC9H19-n, 171-2.degree.; COC11H23, 170-1.degree.. I (R = CF3, R1 = H, R2 = COC9H19-n) was prepd. from Ia, SOCl2, and NaO2CC9H19-n. IIb 14.0, piperazine 7.75, and NaI 6.76 g, with 120 ml EtCOMe was heated 19 hr to give II [R = CF3, R1 = H, R2 = 3-(1-piperazinyl)propyl] (IIc); dimaleate m. 152-5.degree.. IIc (3.91 g) in 20 ml C6H6, 1.71 g Ba(OH)2, 25 mg Cu powder, 50 mg KI, and 1.25 g ClCH2CH2OCH2CH2OH was refluxed 19 hr to give I (R = CF3, R1 = H, R2 = CH2CH2OH). I were used as ataractics and tranquilizers.

IT **27139-87-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 27139-87-3 CAPLUS

CN 1-Piperazineethanol, 4-[3-[7-(trifluoromethyl)dibenz[b,e][1,4]oxazepin-5(11)-yl]propyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 62 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1969:68105 CAPLUS

DOCUMENT NUMBER: 70:68105

TITLE: 5,6,7,12-Tetrahydrodibenz[b,g]azocines and aminoalkylamine derivatives

AUTHOR(S): Fouche, Jean C. L.

CORPORATE SOURCE: Lab. Rech. Pharm., Soc. Usines Chim. RHONE-POULENC, Vitry-sur-Seine, Fr.

SOURCE: Industrie Chimique Belge (1967), 32(Spec. No.), 226-33
CODEN: ICBEAJ; ISSN: 0019-9052

DOCUMENT TYPE: Journal

LANGUAGE: French

GI For diagram(s), see printed CA Issue.

AB Redn. of 2-O2-NC6H4COCl with KBH4 and LiCl in tetrahydrofuran gave 88.5-95% 2-nitrobenzyl alc., m. 70-2.degree., which was oxidized with HNO3 initially at 10.degree. with cooling to give 81-9% 2-O2NC6H4CHO (I), m. 39-42.degree.. NaOEt condensation of I with 2-nitroacetophenone yielded

84-8% 2,2'-dinitrochalcone, m. 135-6.degree., which was reduced with KBH4 to give 73-88.5% 1,3-bis(2-nitrophenyl)-3-propen-1-ol (II), m. 80-90.degree.. Hydrogenation of II over Pt gave 87-91% 1,3-bis-(2-aminophenyl)-1-propanol (III), m. 105-6.degree.; di-N-acetyl deriv. m. 228.degree.. 1,3-Bis(2-acetamidophenyl)-1-chloropropane (IV), m. 160-5.degree., was prepd. with SOCl2. Hydrogenolysis of 169 g. IV over Pd gave 116.5 g. 1,3-bis(acetamidophenyl)propane (V), m. 262.degree.. V was also prepd. in 84% yield by carefully treating III with HClO4 in AcOH followed by hydrogenation and acetylation and in 82-5.5% yield from III and HBr followed by hydrogenolysis and acetylation. Hydrolysis of V with HCl in (CH2OH)2 gave 100% 1,3-bis(2-aminophenyl)propane, m. 71-2.degree.; phosphate (VI) m. 226-30.degree.. Heating VI 90 min. at 290-300.degree. gave 42.5% VII m. 58-60.degree.; Ac deriv. m. 137-8.degree.. Various VIII were prepd. by treating VII with NaH and then chloroamines (method A), with phosgene and a hydroxyamine followed by pyrolysis of the product (method B), with BuLi and a chloroalkyl p-toluenesulfonate followed by treatment of the resulting chloride with an amine (method C), or with BuLi and an ethylene oxide followed by conversion of the resulting alc. through the methanesulfonate to an amine (method D). In one instance using method D, the chain was extended by conversion of the methanesulfonate to the nitrile, redn., and methylation. VIII prepd. were (X, NR'2, method of synthesis, % yield, salt isolated, and m.p. salt listed): (CH2)2, NH2, D, 54, HCl, 193-5.degree.; CH2CHMe, NH2, D, 43, HCl, 215.degree.; (CH2)3, NH2, C, 45, neutral tartrate, 179-81.degree.; CH2CHMe, NHMe, D, 75, HCl, 188-90.degree.; CH2CHMeCH2, NHMe, C, 31, HCl, 201-3.degree.; (CH2)2, NMe2, A, 44 (54), HCl (fumarate), 242-4.degree. (176-8.degree.); CH2CHMe, NMe2, B (D), 25(41), fumarate, 176-8.degree.; (CH2)3, NMe2, A, 49, oxalate, 148-50.degree.; CH2CHMeCH2, NMe2, A (C), 76.5 (41), HCl, 230-2.degree.; (CH2)2, NEt2, A, 12.5, HCl, 176-8.degree.; (CH2)3, NEt2, C, 66, oxalate, 130-3.degree.; CH2CHMeCH2, NEt2, C, 38.5, HCl, 180-3.degree.; CH2CHMe, 1-pyrrolidinyl (Q), D, 31.5, HCl, 200.degree.; (CH2)3, Q, C, 43, neutral tartrate, 128-30.degree.; CH2CHMeCH2, Q, C, 52, HCl, 140.degree. then 210.degree.; (CH2)2, piperidino (T), A, 32.5, HCl, 208-12.degree.; CH2CHMe, T, D, 36, HCl, 182-4.degree.; (CH2)3, T, C, 29, neutral tartrate, 140-2.degree.; CH2CHMeCH2, T, C, 33, HCl, 196-200.degree.; (CH2)2, 4-hydroxypiperidino (U), D, 76.5, neutral tartrate, 194-6.degree.; CH2CHMe, U, D, 67, HCl, 170-5.degree.; (CH2)3, U, C, 61, oxalate, 120-30.degree.; (CH2)3, 4-methylpiperazinyl (V), A, 64, 2 HCl, 198-200.degree.; CH2CHMeCH2, V, C, 46.5, 2 HCl, 198-201.degree.; CH2CHMe, 4-hydroxyethylpiperazino (W), D, 63.5, 2 HCl, 193-7.degree.; (CH2)3, W, C, 68, 2 HCl, 200-2.degree.; CH2CHMeCH2, W, C, 43.5, base, 78.5-81.5.degree.; (CH2)3, 4-hydroxyethoxyethyl-piperazino (Y), C, 71, 2 HCl, 164-6.degree.; CH2CHMeCH2, Y, C, 47.5, base, 78.5-80.5.degree.. Optically active starting materials gave the following VIII (XNR'2 given): Me2NCH2CHMe, [.alpha.]2D2 44.7.degree. (EtOH); and Me2NCH2CHMeCH2, [.alpha.]2D0 27.2 and -26.9.degree. (CHCl3); and the following 12-substituted VII (12 substituent given): ClCO, (m. 154-6.degree.); Me2NCH2CHMeO2C (m. 122-4.degree.); MeSO3CHMeCH (b0.35 160.degree.); MeCH(CN)CH2 (m. 96.degree.).

IT **1252-05-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 1252-05-7 CAPLUS

CN 1-Piperazineethanol, 4-[3-(6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)-2-methylpropyl]- (7CI, 8CI) (CA INDEX NAME)



L8 ANSWER 63 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1968:436093 CAPLUS
DOCUMENT NUMBER: 69:36093
TITLE: The synthesis and pharmacological properties of dibenz[b,e][1,4]oxazepin-11(5H)-ones
AUTHOR(S): Raines, Stephen; Kovacs, Csaba A.; Goldstein, Sidney; Palopoli, Frank P.
CORPORATE SOURCE: Div. of Nat. Drug Co., Richardson-Merrell Inc., Philadelphia, PA, USA
SOURCE: Journal of Medicinal Chemistry (1968), 11(4), 895-6
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB N-(2-Hydroxyphenyl)anthranilic acids and dibenz[b,e][1,4]oxazepin-11(5H)-ones were synthesized and screened for antiinflammatory activity against carrageenin-induced abscesses in rats. When injected locally with carrageenin, N-(2-hydroxyphenyl)anthranilic acid, dibenz[b,e][1,4]oxazepin(5H)-one, 7-methyldibenz[b,e][1,4]oxazepin-11(5H)-one, and 6,7-dimethyldibenz[b,e][1,4]oxazepin-11(5H)-one (I) showed resp. minimal effective concns. (wt./vol.) in carrageenin of 2.7, 0.03, 0.1, and 0.01%. Thus, all 4 compds. have significant local antiinflammatory activity.
IT **15676-55-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and inflammation response to)
RN 15676-55-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-11(5H)-one (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 64 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

09/ 076,575

ACCESSION NUMBER: 1968:29690 CAPLUS
DOCUMENT NUMBER: 68:29690
TITLE: Novel polycyclic heterocycles. IV. Structure of the dimer of 5,11-dihydrodibenz[b,e][1,4]oxazepine. Infrared, proton magnetic resonance, and mass spectral studies
AUTHOR(S): Yale, Harry L.; Sowinski, Francis A.
CORPORATE SOURCE: Squibb Inst. for Med. Res., New Brunswick, NJ, USA
SOURCE: Journal of Medicinal Chemistry (1967), 10(6), 1022-5
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB In the synthesis of 5-[2-(dimethylamino)ethyl]-5,11-dihydrodibenz [b,e] [1,4] oxazepine (I), by the reaction of the anion of the heterocycle with 2-dimethylaminoethyl chloride, one of the by-products isolated from the residue from the distn. of I was identified as 5-[o-[o-[2-(dimethylamino)-ethoxy] - N - [2 - (dimethylamino)ethyl]anilino]benzyl]5,11 - dihydrodibenz[b,e] [1,4]oxazepine (II). In the absence of 2-dimethylaminoethyl chloride, the anion of the heterocycle forms the parent dimer, 5-[o-(o-hydroxyanilino)benzyl]-5,11-dihydrodibenz[b,e] [1,4]oxazepine. The ir, P.M.R., and mass spectra of these and related compds. are discussed.
IT **16882-84-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 16882-84-1 CAPLUS
CN 1,2-Ethanediamine, N-[2-(dibenz[b,e][1,4]oxazepin-5(11H)-ylmethyl)phenyl]-N-[2-[2-(dimethylamino)ethoxy]phenyl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 65 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1967:46414 CAPLUS
DOCUMENT NUMBER: 66:46414
TITLE: Synthesis and rearrangement of dibenz[b,e][1,4]oxazepin-6(11H)-one, depsazidone
AUTHOR(S): Gurien, Harvey; Malarek, David H.; Rachlin, Albert I.
CORPORATE SOURCE: Univ. of Pennsylvania, Philadelphia, PA, USA
SOURCE: Journal of Heterocyclic Chemistry (1966), 3(4), 527-8
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB A mixt. of o-BrC6H4CO2H, HCONMe9, and anhyd. K2CO3 was refluxed (while HCONMe2, was distd. through a sidearm), cooled, CuO, CuCl, HCONMe2, and

192 g. o-H2NC6H4OH were added, the mixt. was refluxed with slow distn. of HCONMe2, and worked up with acidification to yield N-(2-hydroxyphenyl)anthranilic acid (I). SOCl2 in dry Et2O was added to I and pyridine in 6.5l. dry Et2O, the mixt. stirred 3 days, and extd. with N HCl to give a solid, which, dissolved in EtOAc, passed through a silica gel column to give dibenz[b,e][1,4]oxazepin-6(11H)one (depsazidone) (II). Dry HCONMe2 was added to a warmed and stirred mixt. of II and a 53.5% mineral oil suspension of NaH and 90 ml. C6H6, the mixt. was refluxed 18 hrs., cooled, and treated successively with N HCl and N NaHCO3, and filtered to yield 5,11-bis(2-hydroxyphenyl)-5,11-dihydrodibenzo[b,f][1,5]diazocine-6,12-dione (III), m. 267-70.degree. (BuOAc). The rearrangement of II into III was studied by N.M.R. Alk. sapon. of III yielded I. N-(2-methoxy)phenylanthranilic acid (IV) was obtained in a 79.1% yield from o-BrC6H4CO2H and o-H2NC6H4OMe, similarly to I. All attempts to demethylate IV failed.

IT **15676-55-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 15676-55-8 CAPLUS
CN Dibenz[b,e][1,4]oxazepin-11(5H)-one (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 66 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1965:410096 CAPLUS
DOCUMENT NUMBER: 63:10096
ORIGINAL REFERENCE NO.: 63:1775g-h,1776a-e
TITLE: 5-(Aminoalkyl)-5,10,11,12-tetrahydrodibenz [b,g] azocine derivatives
PATENT ASSIGNEE(S): Rhone-Poulenc S.A.
SOURCE: 14 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 983859		19650217	GB	
FR 1403603			FR	
FR AD85301			FR	

PRIORITY APPLN. INFO.: FR 19600705
GI For diagram(s), see printed CA Issue.
AB I were prepd. by two general methods. A mixt. of 6 g. 5,10,11,12-tetrahydrodibenz[b,g]azocine (II), prepd. by the method of Brit. 926,335 (CA 61, 1843g), and 1.03 g. sodamide in 50 cc. anhyd. xylene and 19.8 cc. of a xylene soln. of Me2N(CH2)3Cl (176 g./l.) was stirred under reflux under a current of N for 7 hrs. when the evoution of NH3 ceased to give 5.8 g. I [A = (CH2)3, Q = NMe2] as the acid oxalate, m. 146-7.degree.. The following I were similarly prepd. (A, Q, acid salt, and m.p. given): (CH2)3, 4-methyl-1-piperazinyl, dihydrochloride, 198-200.degree.; CH2CHMe, NMe2, fumarate, 176-8.degree.; CHMeCH2, NMe2, fumarate, 209-11.degree.; CH2CHMeCH2, NMe2, hydrochloride (EtOH of crystn.), 204-7.degree.; (CH2)2, NEt2, hydrochloride, 176-8.degree.;

(CH2)2, NMe2, hydrochloride, 242-4.degree.; (CH2)2, 1-piperidinyl, hydrochloride, 208-12.degree.; CH2CH(NMe2)CH2, NMe2, dihydrochloride, 195-8.degree.; (CH2)2, 1-methyl-2-piperidinyl, dihydrochloride, 140-5.degree.. A soln. of 20.9 g. II in 60 cc. Et2O was added during 15 min. below 10.degree. to an ethereal soln. of BuLi, prepd. from 2.2 g. Li, 17.2 g. BuBr, and 100 cc. Et2O. The temp. was allowed to rise to 17.degree., a soln. of 26.3 g. p-MeC6H4SO3CH2CHMeCH2Cl in 55 cc. Et2O added during 15 min. <25.degree., and the mixt. stirred 3 hrs. at 25.degree. and kept 15 hrs. to give 30 g. 5-(3-chloro-2-methylpropyl)-5, 10, 11, 12-tetrahydrobenz[b,g]azocine (III) as an oily residue. Et2NH (73 g.) was added to 30 g. crude III in 100 cc. anhyd. EtOH and heated at 100.degree. for 21 hrs. in a pressure vessel to give I [A = CH2CHMeCH2, Q = NEt2] as the hydrochloride, m. 180-3.degree.. The following I were similarly prepd. (A, Q, acid salt, and m.p. given): CH2CHMeCH2, 4-hydroxy-1-piperidinyl, -, - (base m. 78-80.5.degree.); CH2CHMeCH2, 4-(2-hydroxyethyl)1-piperazinyl, -, - (base m. 78.5-81.5.degree.); CH2CHMeCH2, 4-methyl-1-piperazinyl, dihydrochloride (2H2O of crystn.), 198-201.degree.; CH2CHMeCH2, NHMe, hydrochloride, 210-13.degree.; (CH2)3, 4-(2-hydroxyethyl)-1-piperazinyl, dihydrochloride, 200-2.degree.; (CH2)3, 4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl, dihydrochloride, 164-6.degree.; CH2CHMeCH2, 4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl, -, - (base m. 78.5-80.5.degree.); CH2CHMeCH2, 1-morpholinyl, hydrochloride, 200-5.degree.; CH2CHMeCH2, 1-piperidinyl, fumarate, 147-51.degree.; CH2CHMeCH2, 1-pyrrolidinyl, hydrochloride (EtOH of crystn.), 140.degree. and 210.degree.; (CH2)3, 4-hydroxy-1-piperidinyl, oxalate, 115.degree.; (CH2)3, 1-morpholinyl, oxalate, 173-5.degree.; (CH2)3, 1-piperidinyl, dihydrochloride, 106-10.degree.; (CH2)3, 1-piperidinyl, tartrate, 140-2.degree.; (CH2)3, 1-pyrrolidinyl, neutral tartrate, 128-30.degree.; (CH2)3, 1-pyrrolidinyl, oxalate, 130-3.degree.. 5-(2-Dimethylaminoethoxycarbonyl) deriv. of II (3.6 g.) was decarboxylated by heating at 230-50.degree. for 45 min. under a current of N. The residue was distd. in vacuo to give 2.2 g. product, b0.4 135-45.degree., which gave I [A = (CH2)2, Q = NMe2] as the hydrochloride, m. 236-9.degree.. II (4.18 g.) in 15 cc. anhyd. Et2O was added to 1.92 g. BuLi in 25 cc. anhyd. Et2O at 8-10.degree.. After stirring for 30 min., the soln. was cooled to 0.degree. 7.5 cc. 4.1M anhyd. ethereal ethylene oxide added at below 10.degree., and the mixt. stirred at room temp. for 15 hrs. to give 5 g. 5-(2-hydroxyethyl) deriv. of II, which was treated in 40 cc. anhyd. pyridine at - 10.degree. with 4.53 g. MeSO2Cl. The oil which sepd. on pouring into 250 cc. H2O was extd. with C6H6. The C6H6 soln. was washed with cold N HCl soln. and H2O, dried over Na2SO4, and concd. to 80 cc. before treating with 40 cc. 5.7M Me2NH in C6H6 at 100.degree. for 17 hrs. to give 3.25 g. I [A = (CH2)2, Q = NMe2] as the hydrochloride. I possess a very high antiemetic and intense antidepressant activity, making them useful for treating melancholia.

IT **1252-05-7**, 1-Piperazineethanol, 4-[3-(6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)-2-methylpropyl]-
(prepn. of)

RN 1252-05-7 CAPLUS

CN 1-Piperazineethanol, 4-[3-(6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)-2-methylpropyl]- (7CI, 8CI) (CA INDEX NAME)



L8 ANSWER 67 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1965:74163 CAPLUS
DOCUMENT NUMBER: 62:74163
ORIGINAL REFERENCE NO.: 62:13131g-h,13132a-d
TITLE: 5,10,11,12-Tetrahydrodibenz[b,g]azocine derivatives
INVENTOR(S): Jacob, Robert M.; Fouche, Jean C. L.
PATENT ASSIGNEE(S): Rhone-Poulenc S.A.
SOURCE: 9 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1180751		19641105	DE	
PRIORITY APPLN. INFO.:			FR	19600705

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepd. 5,10,11,12-Tetrahydrodibenz[b,g]azocine (II) (6.0 g.), 50 ml. dry xylene, 1.03 g. $NaNH_2$, and 19.8 ml. xylene soln. contg. 176 g. 1-dimethylamino-3-chloropropane per 1. soln. was stirred and heated under N at reflux until NH_3 evolution had ceased (7 hrs.), cooled, 100 ml. distd. H_2O added, the xylene layer decanted, washed twice with 50 ml. distd. H_2O, and extd. 3 times with a total of 200 ml. 2N HCl, the acidic soln. made alk. with 100 ml. 10N NaOH, the oil formed extd. with 50 ml. then with 30 ml. Et_2O, the ext. dried (K_2CO_3) and evapd., and the residue in 35 ml. Me_2CO treated with a soln. of 1.75 g. dry oxalic acid in 35 ml. Me_2CO to ppt. 5.8 g. of acid oxalate of 5-(3-dimethylaminopropyl)-5,10,11,12-tetrahydrodibenz[b,g]azocine, m. 146-7.degree.. II, m. 55-7.degree., was prepd. by heating a salt of 1,3-bis(o-aminophenyl)propane at 220-300.degree.. The following I were similarly prepd. (R, salt, and m.p. salt given): 3-(4-methyl-piperazino)propyl, di-HCl, 198-200.degree.; 2-dimethylaminopropyl, fumarate, 176-8.degree.; 3-dimethylamino-2-methylpropyl, HCl (solvate with EtOH), 204-7.degree.; 2-diethylaminoethyl, HCl, 176-8.degree.; 2-piperidinoethyl, HCl, 208-12.degree.; 2',3'-bis(dimethylamino)-propyl, di-HCl, 195-8.degree.; 2-(1-methyl-2-piperidyl)ethyl, di-HCl, 140-5.degree.. Crude 5-(3-chloro-2-methylpropyl)-5,10,11,12-tetrahydrodibenz[b,g]azocine (V) (prepd. by reaction of 3-p-tolyl-sulfonyloxy-2-methyl-1-chloropropane with the Li deriv. of II) (30 g.) was dissolved in 100 ml. dry EtOH, 73 g. Et_2NH added, the mixt. heated 21 hrs. at 100.degree. in a high pressure

flask, and the solvent removed under a slight vacuum to yield an oily residue, which was worked up to give 10.5 g. 5-(3-diethylamino-2-methylpropyl)-5,10,11,12-tetrahydrodibenz[b,g]azocine-HCl, m. 180-3.degree.. The following I were similarly prepd. (R, salt, and m.p. salt given): 3-(4-hydroxypiperidino)-2-methylpropyl, --, 78-80.5.degree. (free base); 3-(4-hydroxyethylpiperazino)-2-methylpropyl, --, 78.5-81.5.degree. (free base); 3-(4-methylpiperazino)-2-methylpropyl, di-HCl dihydrate, 198-201.degree.; 3-methylamino-2-methylpropyl, HCl, 201-3.degree.; 3-(4-hydroxyethoxyethylpiperazino)-2-methylpropyl, --, 78.5-80.5.degree. (free base); 3-morpholino-2-methylpropyl, HCl, 200-5.degree.; 3-piperidino-2-methylpropyl, fumarate, 147-51.degree.; and 3-pyrrolidino-2'-methylpropyl, HCl (solvate with EtOH), 140.degree. and 210.degree.. The following I were prepd. by reaction of 5-(3-chloropropyl)-5,10,11,12-tetrahydrodibenz[b,g]azocine with various amines (R, salt, and m.p. salt given): 3-(4-hydroxyethylpiperazino)propyl, di-HCl, 200-2.degree.; 3-(4-hydroxyethoxyethylpiperazino)propyl, di-HCl, 164-6.degree.; 3-(4-hydroxypiperidino)propyl, oxalate, 115.degree.; 3-morpholinopropyl, oxalate, 173-5.degree.; 3-piperidinopropyl, di-HCl, 106-10.degree.; 3-pyrrolidinopropyl, --, 128-30.degree. (free base); and 3-diethylaminopropyl, oxalate, 130-3.degree.. Similarly prepd. from 5-methyl-sulfonylethyl-5,10,11,12-tetrahydrodibenz[b,g]azocine was I (R = Me2NCH2CH2) (III) HCl salt, m. 242-4.degree.. 5-(2-Dimethyl-aminoethoxycarbonyl) -5,10,11,12-tetrahydrodibenz [b,g] azocine was decarboxylated at 230-50.degree. and the product treated with HCl to yield III. I were antidepressives.

IT **1252-05-7**, 1-Piperazineethanol, 4-[3-(6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)-2-methylpropyl]-
(prepn. of)

RN 1252-05-7 CAPLUS

CN 1-Piperazineethanol, 4-[3-(6,7-dihydrodibenz[b,g]azocin-12(5H)-yl)-2-methylpropyl]- (7CI, 8CI) (CA INDEX NAME)



L8 ANSWER 68 OF 68 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1963:66545 CAPLUS

DOCUMENT NUMBER: 58:66545

ORIGINAL REFERENCE NO.: 58:11386b-g

TITLE: 5-(Aminoalkyl)-5,11-dihydrodibenzoxazepines

INVENTOR(S): Yale, Harry L.; Sowinski, Francis A.; Bernstein, Jack

PATENT ASSIGNEE(S): Olin Mathieson Chemical Corp.

SOURCE: 4 pp.

DOCUMENT TYPE: Patent

09/ 076,575

LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3069432		19621218	US	19610220
FR 1317469			FR	
FR M1845			FR	
GB 951840			GB	

GI For diagram(s), see printed CA Issue.

AB I, where A is a lower alkylene radical of at least 2 C atoms, B is a satd. N-contg. radical of less than 12 C atoms and R and R' are the same or different and are H, halogen, lower alkyl, lower alkoxy, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, or N,N-dimethylsulfonamido, and their salts are useful as ataractic agents and as antihistamines. I are prepd. by a series of 6 reactions. Thus, a mixt. of 188 g. .omicron.-bromotoluene, 178 g. N-bromosuccinimide, 1.5 g. Bz2O2, and 350 ml. CCl4 is stirred and refluxed for 34 hrs. The mixt. is cooled, filtered, concd., and cooled again, and the residue washed with 15% aq. NaHSO3, H2O, 15% aq. FeSO4, and H2O, and dried (anhyd. MgSO4) to yield 161.3 g. .omicron.-bromobenzyl bromide (II), b10 122-6.degree.. To a stirred soln. of 119.5 g. II, and 83.6 g. .omicron.-nitrophenol in 400 ml. 95% EtOH, a soln. of 39.6 g. 85% KOH in 200 ml. H2O is added dropwise and the mixt. refluxed for 2 hrs. Cooling, filtering, washing (H2O), and drying yields 149.6 g. .omicron.-bromobenzyl .omicron.-nitrophenyl ether (III), m. 82.5-3.0.degree. (95% EtOH). To a stirred mixt. of 149.0 g. III, 270 g. Fe powder, and 3.5 l. 95% EtOH is added 25 ml. concd. HCl. After refluxing 1 hr., the mixt. is filtered hot, concd. until 2 phases appear, cooled, and extd. with Et2O. Concn. of the dried Et2O ext. yields 101.1 g. 2-(.omicron.-bromobenzyloxy)aniline (IV), m. 48-9.degree.. To a mixt. of 169.0 g. 98-100% HCO2H and 73.5 g. HOAc is added in small portions with cooling and stirring 101.1 g. IV. The mixt. is refluxed for 1/2 hr. and concd. in vacuo to yield about 104 g. 2-(.omicron.-bromobenzyloxy) formanilide (V), m. 113.5-14.degree. [Skellysolve V (VI.)]. A stirred mixt. of 5.0 g. V, 2.8 g. anhyd. K2CO3, 0.5 g. Cu powder, and 50 ml. HCONMe2 is heated under N at 155-60.degree. for 2 hrs. The mixt. is filtered hot, concd. to dryness, washed (H2O), and extd. with VI to yield, on cooling, 2.6 g. I (R = R' = H, AB = CHO) (VII). Addnl. recrystn. (hexane and VI resp.) yields 0.9 g. pure VII, m. 111.5-12.5. VII (100 mg.) is dissolved in a mixt. of 10 ml. EtOH and 2 ml. 10% aq. NaOH. The soln. is refluxed for 1 hr., cooled, neutralized, and concd. to dryness to yield I (R = R' = AB = H), m. 118-18.5 (hexane). Similarly, using 2-bromo-4-chlorobenzyl bromide instead of II gave I (R = AB = H,R'=3-Cl). Also prepd. were I (R,R', and AB given): H, 3-F3C, H; 7-Me, H, H; 7-Cl, 3-Cl, H; H, 3-SO2NH2, H; H, 3-CF3, H; H, 3-F3CS, H; H, H, (CH2)3NMe2 (VIII) (b0.15 138-43.degree.); H, 3-Cl, (CH2)3NMe2; H, 3-CF3, (CH2)3NMe2; 7-Me, H, (CH2)3NMe2; 7-Cl, 3-Cl, (CH2)3NMe2; H, H; CH2-CH2NMe2; H, H, 3-(N4-methylpiperazino)propyl; H, H, 3-[N4-(2-hydroxyethyl)piperazino]propyl; H, H, 3-[N4-(2-hydroxyethoxyethyl)piperazino]propyl; H, H, 3-[N4-(2-acetoxyethyl)piperazino] propyl.

IT **105476-69-5**, Ethanol, 2-[2-[4-(3-dibenz[b,e][1,4]oxazepin-5-(11H)-ylpropyl)-1-piperazinyl]ethoxy]-
(prepn. of)

RN 105476-69-5 CAPLUS

CN Ethanol, 2-[2-[4-(3-dibenz[b,e][1,4]oxazepin-5(11H)-ylpropyl)-1-piperazinyl]ethoxy]- (7CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 14:34:21 ON 03 SEP 2003)

     FILE 'REGISTRY' ENTERED AT 14:34:52 ON 03 SEP 2003
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3              0 S L1 FUL
L4              0 S L2 FUL
L5             45 S 'DIBENZ[B,G]AZOCIN'
L6            203 S 'DIBENZ[B,E][1,4]OXAZEPIN'
L7              0 S 'DIBENZ[D,G]DIOXAZOCIN'

     FILE 'CAPLUS' ENTERED AT 14:41:00 ON 03 SEP 2003
L8             68 S L5 OR L6

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     311.37     653.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -44.27     -44.27

STN INTERNATIONAL LOGOFF AT 14:44:59 ON 03 SEP 2003
```